[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 183
1. Coche D, Bergues B, Harrivel V, Guillaume N: [Biphenotypic acute leukaemia with Burkitt-like cytology]. Ann Biol Clin (Paris); 2009 Jul-Aug;67(4):437-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia with Burkitt-like cytology].
  • [Transliterated title] Leucémie aiguë biphénotypique avec aspect cytologique de type Burkitt.
  • Biphenotypic acute leukaemia (BAL) represents about 5% of adult acute leukaemia.
  • Here, we report the case of a BAL with Burkitt-like cytology, corresponding to "the acute lymphoblastic leukaemia, Burkitt type" L3 for the FAB classification.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / genetics
  • [MeSH-minor] Adult. Blast Crisis / pathology. Burkitt Lymphoma / pathology. Flow Cytometry / methods. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654084.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


2. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H: Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1569-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
  • BACKGROUND: Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL.
  • CONCLUSIONS: The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


3. Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CE, Harrington WJ Jr, Bacchi CE: Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol; 2008 Dec;130(6):946-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in Brazil is characterized by geographically distinct clinicopathologic features.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma with a consistent MYC translocation.
  • This is a large-scale study of BL in Brazil, including 234 patients from 5 geographic regions that are widely disparate socioeconomically, including pediatric (61.1%) and adult (37.6%) populations.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4273-6 [1638540.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Leukemia. 1992 Sep;6(9):875-8 [1325581.001]
  • [Cites] Blood. 1993 Jul 15;82(2):619-24 [8392401.001]
  • [Cites] Am J Clin Pathol. 1994 Jun;101(6):773-82 [8209868.001]
  • [Cites] Br J Haematol. 1995 Jan;89(1):55-60 [7833277.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Am J Clin Pathol. 1996 Feb;105(2):230-7 [8607450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Cancer. 1998 Feb 15;82(4):766-74 [9477111.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Eur J Cancer. 2004 Dec;40(18):2781-7 [15571961.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):237-42 [16082248.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1599-607 [16249378.001]
  • [Cites] Rev Soc Bras Med Trop. 2006 Jan-Feb;39(1):27-31 [16501762.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Int J Lab Hematol. 2007 Aug;29(4):229-60 [17617076.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):558-64 [17875505.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1436-42 [18316607.001]
  • [Cites] Haematologica. 2008 May;93(5):780-3 [18367488.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]
  • [Cites] Leukemia. 2001 Nov;15(11):1729-34 [11681414.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] Pediatr Blood Cancer. 2004 Aug;43(2):115-9 [15236276.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2004;99(5 Suppl 1):13-9 [15486629.001]
  • [Cites] Cancer. 1971 Jul;28(1):89-98 [4938894.001]
  • [Cites] Science. 1983 Nov 18;222(4625):765-71 [6356357.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;141:128-37 [2850892.001]
  • [Cites] Blood. 1991 Apr 1;77(7):1516-26 [1849033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5413-7 [2052620.001]
  • [Cites] Blood. 1991 Dec 1;78(11):3004-11 [1659471.001]
  • [Cites] J Pathol. 1992 Mar;166(3):235-41 [1381424.001]
  • (PMID = 19019773.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / D43 TW000017; United States / NCI NIH HHS / CA / 5R01 CA082274; United States / NCI NIH HHS / CA / R01 CA163217; United States / NIDCR NIH HHS / DE / DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / R01 CA112217; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / 5R01 CA121935; United States / NCI NIH HHS / CA / R01 CA121935; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NCI NIH HHS / CA / 5R01 CA112217
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ NIHMS191353; NLM/ PMC2866005
  •  go-up   go-down


Advertisement
4. Giacomin PR, Wang H, Gordon DL, Botto M, Dent LA: Loss of complement activation and leukocyte adherence as Nippostrongylus brasiliensis develops within the murine host. Infect Immun; 2005 Nov;73(11):7442-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Substantive deposition of C3 and adherence of eosinophil-rich leukocytes were seen with infective-stage (L3) but not with lung-stage (L4) larvae.
  • Adult intestinal worms had low to intermediate levels of both C3 and leukocyte binding.
  • For L3 and adult worms, complement deposition was principally dependent on the alternative pathway.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Trop Med Hyg. 1980 Sep;29(5):842-8 [7435788.001]
  • [Cites] Aust J Exp Biol Med Sci. 1979 Oct;57(5):459-66 [548018.001]
  • [Cites] Parasite Immunol. 1983 Mar;5(2):183-94 [6601790.001]
  • [Cites] Adv Parasitol. 1984;23:143-235 [6397977.001]
  • [Cites] Acta Trop. 1985 Jun;42(2):157-63 [2862778.001]
  • [Cites] Exp Parasitol. 1986 Feb;61(1):86-94 [3943595.001]
  • [Cites] Science. 1986 Oct 31;234(4776):603-7 [3094145.001]
  • [Cites] Parasite Immunol. 1987 Jan;9(1):133-43 [3550601.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1987 Mar;18(1):66-72 [3660070.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(5):1657-61 [2964038.001]
  • [Cites] Exp Parasitol. 1988 Apr;65(2):157-67 [2450771.001]
  • [Cites] J Immunol. 1988 Jul 1;141(1):273-8 [3132503.001]
  • [Cites] Mem Inst Oswaldo Cruz. 1987;82 Suppl 4:213-6 [2474124.001]
  • [Cites] Eur J Immunol. 1990 Jan;20(1):221-7 [2307175.001]
  • [Cites] J Parasitol. 1990 Jun;76(3):377-82 [2352068.001]
  • [Cites] Curr Opin Immunol. 2000 Feb;12(1):44-51 [10679403.001]
  • [Cites] J Immunol. 2000 Oct 15;165(8):4544-51 [11035095.001]
  • [Cites] Exp Parasitol. 2000 Aug;95(4):231-9 [11038306.001]
  • [Cites] Parasite Immunol. 2001 Jan;23(1):27-37 [11136475.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1786-93 [12085326.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5604-11 [12228288.001]
  • [Cites] J Helminthol. 2003 Jun;77(2):119-24 [12756065.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6402-10 [14573661.001]
  • [Cites] Immunity. 2004 Mar;20(3):267-77 [15030771.001]
  • [Cites] Parasite Immunol. 2003 Nov-Dec;25(11-12):545-52 [15053775.001]
  • [Cites] J Immunol Methods. 2004 Jun;289(1-2):201-10 [15251425.001]
  • [Cites] Infect Immun. 2004 Nov;72(11):6633-41 [15501796.001]
  • [Cites] J Cell Physiol. 1977 Mar;90(3):535-52 [856837.001]
  • [Cites] J Immunol. 1979 Oct;123(4):1551-7 [113459.001]
  • [Cites] Ann Trop Med Parasitol. 1990 Apr;84(2):185-91 [2200361.001]
  • [Cites] Int J Parasitol. 1990 Aug;20(5):587-93 [2228422.001]
  • [Cites] J Exp Med. 1990 Nov 1;172(5):1425-31 [2230651.001]
  • [Cites] Parasite Immunol. 1991 Jan;13(1):13-22 [2014134.001]
  • [Cites] Exp Parasitol. 1992 May;74(3):290-9 [1582481.001]
  • [Cites] Parasitology. 1993 Jun;106 ( Pt 5):463-9 [8341582.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4 [8524789.001]
  • [Cites] Parasitol Res. 1995;81(5):398-402 [7501639.001]
  • [Cites] J Immunol. 1996 Jul 15;157(2):549-56 [8752901.001]
  • [Cites] Parasite Immunol. 1995 Nov;17(11):555-9 [8817601.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8720-5 [9238044.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Oct;114 Suppl 1:45-50 [9363925.001]
  • [Cites] Parasite Immunol. 1998 Feb;20(2):93-103 [9572052.001]
  • [Cites] Nat Genet. 1998 May;19(1):56-9 [9590289.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):989-93 [9916122.001]
  • [Cites] Infect Immun. 1999 Oct;67(10):5315-23 [10496911.001]
  • [Cites] J Immunol. 1980 Jun;124(6):2886-91 [6989909.001]
  • [Cites] J Pathol. 1981 Feb;133(2):161-75 [7205445.001]
  • (PMID = 16239545.001).
  • [ISSN] 0019-9567
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Complement C3; 0 / Complement C4; 80295-33-6 / Complement C1q; EC 3.4.21.47 / Complement Factor B
  • [Other-IDs] NLM/ PMC1273855
  •  go-up   go-down


5. Simcock DC, Brown S, Neale JD, Przemeck SM, Simpson HV: L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake. Exp Parasitol; 2006 Jan;112(1):1-7
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] L3 and adult Ostertagia (Teladorsagia) circumcincta exhibit cyanide sensitive oxygen uptake.
  • Oxygen consumption by L3 and adult Ostertagia (Teladorsagia) circumcincta was examined in vitro to determine whether oxygen can be utilised in metabolism.
  • Rates of consumption (in nmol O2/h/1000 worms) were 13+/-1 in sheathed L3, 34+/-6 in ex-sheathed L3, and 1944+/-495 in adult worms.
  • Consumption was inhibited 95% by cyanide in L3 and 74% in adults.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. POTASSIUM CYANIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16198342.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] IY9XDZ35W2 / Glucose; MQD255M2ZO / Potassium Cyanide; S88TT14065 / Oxygen
  •  go-up   go-down


6. Oriol A, Ribera JM, Bergua J, Giménez Mesa E, Grande C, Esteve J, Brunet S, Moreno MJ, Escoda L, Hernandez-Rivas JM, Hoelzer D: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer; 2008 Jul 1;113(1):117-25
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
  • BACKGROUND: It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. HIV Infections / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Drug Administration Schedule. Feasibility Studies. Female. Humans. Immunotherapy. Male. Middle Aged. Remission Induction. Rituximab. Survival Analysis

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457327.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Tachu B, Pillai S, Lucius R, Pogonka T: Essential role of chitinase in the development of the filarial nematode Acanthocheilonema viteae. Infect Immun; 2008 Jan;76(1):221-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Northern blot experiments and rapid amplification of cDNA ends-PCR with adult worms and larval stages showed that only one gene is expressed, with high variation in transcript levels, as determined by real-time PCR.
  • Chitinase transcript levels were lowest in the late male stage 4 larva (L4) and peaked in the stage 3 larva (L3), which was corroborated by Western blotting.
  • RNA interference (RNAi) experiments showed that treatment of L3 and adult female worms with double-stranded RNA of chitinase inhibited molting of L3 worms and hatching of microfilariae.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Biochem Parasitol. 1996 Jan;75(2):207-19 [8992319.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1441-7 [8576136.001]
  • [Cites] Exp Parasitol. 1999 Oct;93(2):73-81 [10502469.001]
  • [Cites] Parasitology. 2004 Dec;129(Pt 6):655-61 [15648688.001]
  • [Cites] Dev Biol. 2005 Sep 15;285(2):330-9 [16098962.001]
  • [Cites] Genome Res. 1999 Nov;9(11):1026-39 [10568743.001]
  • [Cites] Parasitol Today. 1999 Mar;15(3):123 [10322327.001]
  • [Cites] J Biol Chem. 2000 Jun 16;275(24):17929-32 [10770921.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 15;29(12):2581-93 [11410667.001]
  • [Cites] Mol Genet Genomics. 2001 Sep;266(1):28-34 [11589574.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42557-64 [11535590.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Insect Biochem Mol Biol. 2003 Jun;33(6):631-48 [12770581.001]
  • [Cites] Mol Biochem Parasitol. 2003 Jun;129(1):41-51 [12798505.001]
  • [Cites] Eur J Biochem. 2004 Jan;271(2):253-62 [14717693.001]
  • [Cites] Parasitology. 1980 Oct;81(2):447-63 [7003502.001]
  • [Cites] Mol Biochem Parasitol. 1985 Oct;17(1):93-104 [3932852.001]
  • [Cites] Mol Biochem Parasitol. 1987 Oct;25(3):267-72 [3696175.001]
  • [Cites] Methods Enzymol. 1990;183:252-78 [2314278.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1548-52 [1542646.001]
  • [Cites] Comp Biochem Physiol B. 1992 Nov;103(3):681-6 [1458842.001]
  • [Cites] Mol Biochem Parasitol. 1993 Apr;58(2):317-23 [8479456.001]
  • [Cites] J Biol Chem. 1993 Sep 5;268(25):18567-72 [8103047.001]
  • [Cites] Infect Immun. 1994 May;62(5):1901-8 [8168956.001]
  • [Cites] Appl Parasitol. 1995 Feb;36(1):22-33 [7780447.001]
  • [Cites] Mol Biochem Parasitol. 1996 Oct 1;80(2):149-58 [8892292.001]
  • (PMID = 17938220.001).
  • [ISSN] 1098-5522
  • [Journal-full-title] Infection and immunity
  • [ISO-abbreviation] Infect. Immun.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF052872/ EF052873/ U14638
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Helminth Proteins; EC 3.2.1.14 / Chitinase
  • [Other-IDs] NLM/ PMC2223640
  •  go-up   go-down


8. Kelly JL, Toothaker SR, Ciminello L, Hoelzer D, Holte H, LaCasce AS, Mead G, Thomas D, Van Imhoff GW, Kahl BS, Cheson BD, Magrath IT, Fisher RI, Friedberg JW: Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma; 2009 Aug;9(4):307-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
  • Burkitt lymphoma is a highly curable disorder when treated with modern intensive chemotherapy regimens.
  • The majority of adult patients with Burkitt lymphoma in the United States are over age 40 years.
  • We therefore obtained and analyzed primary data from 14 Burkitt lymphoma treatment series and confirmed that older patients (age > 40 years) are underrepresented in the literature.
  • We conclude that (1) modern intensive chemotherapy regimens should remain the standard of care for patients > age 40 with Burkitt lymphoma;.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Oncology (Williston Park). 2008 Nov 30;22(13):1508-17 [19133605.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2232-3 [12805320.001]
  • [Cites] Cancer. 2004 Apr 1;100(7):1438-48 [15042678.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):761-7 [15160953.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Br J Haematol. 1989 Mar;71(3):371-6 [2930722.001]
  • [Cites] Ann Hematol. 1992 Nov;65(5):201-5 [1457577.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] Blood. 1996 Jan 15;87(2):495-508 [8555471.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1569-80 [16502413.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):118-47 [17335683.001]
  • [Cites] Cancer Invest. 2007 Mar;25(2):87-93 [17453819.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5316-9 [18854560.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • (PMID = 19717381.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NCI NIH HHS / CA / CA031946-27; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NCI NIH HHS / CA / U10 CA031946; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / CA031946-28; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NHLBI NIH HHS / HL / HL007152; United States / NHLBI NIH HHS / HL / T32 HL007152-32; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / U10 CA031946-27
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207721; NLM/ PMC2909640
  •  go-up   go-down


9. Kenkre VP, Stock W: Burkitt lymphoma/leukemia: improving prognosis. Clin Lymphoma Myeloma; 2009;9 Suppl 3:S231-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma/leukemia: improving prognosis.
  • Burkitt lymphoma/leukemia (BL) has become a very curable mature B-cell neoplasm.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Gene Expression Regulation, Neoplastic. Leukemia / diagnosis. Leukemia / therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. Child. Clinical Trials as Topic. Gene Expression Profiling. HIV Infections / complications. HIV Infections / drug therapy. Humans. Medical Oncology. Prognosis. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778846.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 47
  •  go-up   go-down


10. Hoffmann C, Wolf E, Wyen C, Fätkenheuer G, Van Lunzen J, Stellbrink HJ, Stoehr A, Plettenberg A, Jaeger H, Noppeney R, Hentrich M, Goekbuget N, Hoelzer D, Horst HA: AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma; 2006 Sep;47(9):1872-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective.
  • The objective was to evaluate the feasibility and efficacy of a short-term, multi-agent and dose intensive regimen in AIDS patients with Burkitt or Burkitt-like lymphoma (BL/BLL) and to compare its efficacy with that of a conventional regimen.
  • Group A received a protocol which was adapted from the German multi-center study group for adult acute lymphoblastic leukemia (GMALL).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adult. Antiretroviral Therapy, Highly Active. Cohort Studies. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Doxorubicin / therapeutic use. Drug Therapy, Combination. Feasibility Studies. Female. Humans. Male. Prednisolone / administration & dosage. Prednisone / therapeutic use. Prognosis. Prospective Studies. Remission Induction. Retrospective Studies. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065000.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


11. Keller C, Savage DG, Rusta-Villa M, Bhagat G, Alobeid B: Primary Burkitt lymphoma of the uterine corpus. Leuk Lymphoma; 2006 Jan;47(1):141-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Burkitt lymphoma of the uterine corpus.
  • This study reports the first well-documented case of sporadic Burkitt lymphoma arising in and confined to the uterine corpus in a 40-year-old woman who presented with vaginal bleeding.
  • Endometrial curettings showed a diffuse infiltrate of medium sized lymphocytes with the characteristic morphologic and immunophenotypic features of Burkitt lymphoma.
  • This report demonstrates that Burkitt lymphoma can present as isolated, organ confined disease at unusual sites and with protean symptoms.
  • [MeSH-major] Burkitt Lymphoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Female. Humans. Hysterectomy. In Situ Hybridization, Fluorescence / methods. Sensitivity and Specificity. Translocation, Genetic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321839.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Murthy PK, Dixit S, Gaur RL, Kumar R, Sahoo MK, Shakya N, Joseph SK, Palne S, Gupta S: Influence of Brugia malayi life stages and BmAFII fraction on experimental Leishmania donovani infection in hamsters. Acta Trop; 2008 May;106(2):81-9
Hazardous Substances Data Bank. NITRIC OXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The influence of live Brugia malayi parasites and a Sephadex G-200 fraction of the adult parasite extract (BmAFII) on the progression of Leishmania donovani infection was studied.
  • Inbred hamsters were first infected with B. malayi infective 3rd stage larvae (L3), adult worms or microfilariae (mf), and then with L. donovani amastigotes (Ld), or vice versa or received both the infections simultaneously; a group of animals were first immunized with BmAFII and then infected with Ld. L. donovani parasite burden was determined between 17 and 19 days post amastigote challenge (p.a.c.) and, in case of immunized animals, between 32 and 35 days p.a.c also.
  • Leishmanial parasite burden was significantly reduced in animals exposed to filarial L3 before amastigote inoculation and in animals given filarial adult worms after or together with amastigotes.
  • The findings show, for the first time, that B. malayi L3/adult worms or immunization with BmAFII inhibits progression of L. donovani infection in hamsters and this is associated with upregulation of NO and lymphocyte proliferative responses indicating that Th1 response might be responsible for this.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329620.001).
  • [ISSN] 0001-706X
  • [Journal-full-title] Acta tropica
  • [ISO-abbreviation] Acta Trop.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Helminth; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


13. Díaz-Camacho SP, Delgado-Vargas F, Willms K, de la Cruz-Otero Mdel C, Guadalupe Rendón-Maldonado J, Robert L, Antuna S, Nawa Y: Intrahepatic growth and maturation of Gnathostoma turgidum in the natural definitive opossum host, Didelphis virginiana. Parasitol Int; 2010 Sep;59(3):338-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results show that tiny (<3mm in length) third stage larvae (L3) appeared in the liver of opossums around November and December.
  • Also in the liver, we found large L3 of up to about 10mm in length together with juveniles and mature adults from February to March.
  • In spite of their length, large L3 have 4 rows of hooklets, and their gonads remained undeveloped.
  • Morphological features of the small and large L3 of G. turgidum are described including scanning electron microscope images.
  • The seasonal switching of the several growth stages of G. turgidum from small L3 to adult worms in the liver and eventual migration to the stomach in opossums suggests the unique feature of G. turgidum utilizing the liver as the maturation site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447468.001).
  • [ISSN] 1873-0329
  • [Journal-full-title] Parasitology international
  • [ISO-abbreviation] Parasitol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Helminth; 0 / DNA, Ribosomal Spacer
  •  go-up   go-down


14. van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van 't Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON): Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia; 2005 Jun;19(6):945-52
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
  • The feasibility and efficacy of up-front high-dose sequential chemotherapy followed by autologous stem cell transplantation (ASCT) in previously untreated adults (median age 33 years; range 15-64) with Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or lymphoblastic lymphoma (LyLy), both without central nervous system or extensive bone marrow involvement was investigated in a multicenter phase II study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Burkitt Lymphoma / drug therapy. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Prednisone / administration & dosage. Prednisone / adverse effects. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800666.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Xie X, Xu W, Qiu H: [The cytogenetic features of Burkitt leukemia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr;25(2):214-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The cytogenetic features of Burkitt leukemia].
  • OBJECTIVE: To evaluate the incidence of chromosomal abnormalities in Burkitt leukemia (BL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393250.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


16. Geiger SM, Fujiwara RT, Santiago H, Corrêa-Oliveira R, Bethony JM: Early stage-specific immune responses in primary experimental human hookworm infection. Microbes Infect; 2008 Nov-Dec;10(14-15):1524-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After an initial rise in proliferative responses against larval and adult worm antigens, the cellular reactivity decreased until the end of pre-patency, rose again during patency, and dropped after chemotherapy.
  • Before infection and during the course of infection, elevated concentrations of TNF-alpha were detected in supernatants of peripheral blood mononuclear cells (PBMC) stimulated in vitro with third-stage (L3) or adult worm excretory-secretory (ES) antigens, which dropped off after chemotherapy.
  • After stimulation with L3 antigen, elevated concentrations of CCL17 were detected in supernatants during pre-patency and patency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848637.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Grant] United States / FIC NIH HHS / TW / K01TW00009
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Chemokine CCL17; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10
  •  go-up   go-down


17. Burmeister T, Schwartz S, Horst HA, Rieder H, Gökbuget N, Hoelzer D, Thiel E: Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia; 2005 Aug;19(8):1391-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features.
  • Chromosomal translocations involving the MYC oncogene are a hallmark of Burkitt lymphoma but they are only found in a varying frequency in mature Burkitt-type acute lymphoblastic leukemia (B-ALL).
  • We have investigated samples of 56 sporadic Burkitt leukemia/lymphoma patients for the translocations t(8;14)(q24;q32), t(2;8)(p11;q24) and t(8;22)(q24;q11).
  • A typical L3 or L3-compatible cytomorphology was highly predictive (>80%) but not specific of a MYC translocation.
  • [MeSH-major] Burkitt Lymphoma / genetics. Genetic Heterogeneity. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Cytogenetic Analysis. Female. Genes, myc. Humans. Immunoglobulin Heavy Chains / genetics. Male. Middle Aged. Polymerase Chain Reaction. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1391-1398.
  • (PMID = 15973450.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


18. García-Coiradas L, Angulo-Cubillán F, Méndez S, Larraga V, de la Fuente C, Cuquerella M, Alunda JM: Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus. Parasitol Res; 2009 Jan;104(2):363-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolation and immunolocalization of a putative protective antigen (p26/23) from adult Haemonchus contortus.
  • The putative protective antigen, p26/23, from adult Haemonchus contortus was isolated.
  • A soluble extract from adult helminths obtained from the abomasa of hyperinfected (12,000 infective larvae) female Manchego lambs and treated with a mixture of protease inhibitors was subjected to affinity chromatography (hexylgluthatione) to eliminate the enzyme gluthatione S-transferase.
  • This allowed the isolation of a single protein, which was expressed in both infective larvae (L3) and the adult stage of the parasite.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Parasitol Res. 1998 Aug;84(8):623-31 [9747934.001]
  • [Cites] Exp Parasitol. 1998 Jan;88(1):34-42 [9501846.001]
  • [Cites] Infect Immun. 1994 Nov;62(11):4762-7 [7927752.001]
  • [Cites] Parasitol Res. 2000 Mar;86(3):200-6 [10726990.001]
  • [Cites] Methods Mol Biol. 1992;10:7-12 [23150291.001]
  • [Cites] Parasite Immunol. 2003 May;25(5):283-96 [12969446.001]
  • [Cites] Parasitology. 1997 Mar;114 ( Pt 3):293-9 [9075348.001]
  • [Cites] Trends Parasitol. 2004 Oct;20(10):469-76 [15363440.001]
  • [Cites] Vaccine. 2004 Jan 26;22(5-6):618-28 [14741153.001]
  • [Cites] Rev Sci Tech. 2007 Apr;26(1):105-15 [17633296.001]
  • [Cites] Parasite Immunol. 2000 Mar;22(3):131-8 [10672194.001]
  • [Cites] Br J Nutr. 1988 Jan;59(1):125-39 [3257884.001]
  • [Cites] Int J Parasitol. 2001 Mar;31(3):231-44 [11226449.001]
  • [Cites] Int J Parasitol. 2004 Aug;34(9):1037-45 [15313130.001]
  • [Cites] Mol Biochem Parasitol. 1997 Sep;88(1-2):203-13 [9274880.001]
  • [Cites] Am J Vet Res. 1984 Feb;45(2):230-3 [6608886.001]
  • [Cites] Mol Biochem Parasitol. 1998 Mar 15;91(2):221-35 [9566516.001]
  • [Cites] Parasite Immunol. 1997 Oct;19(10):447-53 [9372512.001]
  • [Cites] Int J Parasitol. 1987 Feb;17(2):443-51 [3294656.001]
  • [Cites] Parasite Immunol. 1999 Apr;21(4):201-10 [10320617.001]
  • [Cites] Br Vet J. 1990 Nov-Dec;146(6):543-50 [2271911.001]
  • [Cites] Int J Parasitol. 1997 Apr;27(4):359-66 [9184927.001]
  • [Cites] Vet Parasitol. 1991 Mar;38(2-3):131-43 [1858283.001]
  • [Cites] Parasitology. 1993 Jan;106 ( Pt 1):63-6 [8479802.001]
  • [Cites] Int J Parasitol. 1993 Apr;23(2):261-9 [8496009.001]
  • [Cites] Parasitology. 2000;120 Suppl:S95-107 [10874713.001]
  • [Cites] Trop Med Int Health. 1997 May;2(5):472-81 [9217703.001]
  • [Cites] Int J Parasitol. 1991 Nov;21(7):839-46 [1774119.001]
  • [Cites] J Infect Dis. 2003 Feb 1;187(3):484-94 [12552433.001]
  • [Cites] J Biol Chem. 1996 Jan 19;271(3):1645-50 [8576165.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] Anal Biochem. 1977 Oct;82(2):334-41 [907137.001]
  • [Cites] Vet Parasitol. 1997 Nov;72(3-4):285-97; discussion 297-308 [9460203.001]
  • [Cites] Am J Vet Res. 1992 Jul;53(7):1263-5 [1497200.001]
  • (PMID = 18825413.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth
  •  go-up   go-down


19. Choi KA, Lee JE, Kim YG, Kim DJ, Kim K, Ko YH, Oh HY, Kim WS, Huh W: Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. Ann Hematol; 2009 Jul;88(7):639-45
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
  • Tumor lysis syndrome (TLS) is a potentially fatal metabolic complication of chemotherapy for Burkitt lymphoma.
  • This retrospective study evaluated the efficacy and safety of continuous venovenous hemofiltration (CVVH) with prephase chemotherapy using the modified LMB-89 regimen in patients with Burkitt lymphoma and leukemia (BL/L) at a high risk of developing TLS from February 1998 to February 2007.
  • Eight patients had Burkitt lymphoma and three had Burkitt leukemia; their median age was 48 years.
  • In conclusion, chemotherapy combined with CVVH might be effective and safe in patients with advanced Burkitt lymphoma and leukemia at a high risk of developing TLS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / therapy. Hemofiltration / methods. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Hydrocortisone / administration & dosage. Hyperuricemia. Kidney Function Tests. Leucovorin / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Prognosis. Retrospective Studies. Risk. Survival Analysis. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19030857.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate; LMB89 protocol
  •  go-up   go-down


20. Huber A, Prosl H, Joachim A, Simpson HV, Pedley KC: Effects of excretory/secretory products of Haemonchus contortus on cell vacuolation. Parasitol Res; 2005 Jul;96(5):290-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have used the latter approach to examine, at the cellular level, the effects of ES prepared from L3 and adult nematodes.
  • Both NR uptake and cellular vacuolation were increased following exposure to larval or adult ES products.
  • ES preparations from adult worms induced more extensive vacuolation then those from L3 worms and, as with VacA treatment, adherent cells remained viable despite high levels of vacuolation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 1974 Sep 15;23 (18):2495-531 [4606365.001]
  • [Cites] Int J Parasitol. 1985 Apr;15(2):159-65 [3997348.001]
  • [Cites] J Infect Dis. 1990 Jun;161(6):1302-4 [2345308.001]
  • [Cites] Int J Parasitol. 1997 Jul;27(7):825-31 [9279586.001]
  • [Cites] J Parasitol. 1986 Apr;72(2):339-45 [3734999.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 19;262(1):245-50 [10448099.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4197-203 [8926088.001]
  • [Cites] Exp Parasitol. 1982 Dec;54(3):371-8 [6891337.001]
  • [Cites] Infect Immun. 1998 Aug;66(8):3981-4 [9673292.001]
  • [Cites] Int J Parasitol. 1996 Oct;26(10):1063-74 [8982786.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] J Physiol Pharmacol. 1993 Mar;44(1):17-22 [8518421.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):243-55 [11812622.001]
  • [Cites] Vet J. 2000 May;159(3):238-51 [10775468.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):C48-58 [9038810.001]
  • [Cites] Gut. 1992 Dec;33(12):1612-6 [1487161.001]
  • [Cites] J Parasitol. 1996 Apr;82(2):197-202 [8604083.001]
  • [Cites] Appl Biochem Biotechnol. 1991 Jul;30(1):29-41 [1952924.001]
  • [Cites] Vet Parasitol. 2000 Mar 28;89(1-2):79-94 [10729648.001]
  • [Cites] N Z Vet J. 1999 Feb;47(1):20-4 [16032062.001]
  • [Cites] Infect Immun. 1991 Apr;59(4):1264-70 [2004808.001]
  • [Cites] Vet Parasitol. 2002 Mar 20;104(3):217-28 [11812620.001]
  • [Cites] J Biotechnol. 1996 May 15;46(3):161-85 [8672289.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G400-10 [10915650.001]
  • [Cites] Infect Immun. 1998 Jun;66(6):2943-50 [9596771.001]
  • [Cites] J Clin Pathol. 1988 May;41(5):597 [3384991.001]
  • [Cites] J Parasitol. 1963 Aug;49:698-9 [14050253.001]
  • [Cites] Am J Physiol. 1990 May;258(5 Pt 1):G719-27 [2159239.001]
  • [Cites] J Cell Biol. 1981 Sep;90(3):656-64 [7287819.001]
  • [Cites] Am J Vet Res. 1981 Mar;42(3):498-502 [7271014.001]
  • [Cites] Gut. 1996 Dec;39(6):795-9 [9038659.001]
  • [Cites] Parasitol Res. 2005 Feb;95(3):213-7 [15723269.001]
  • [Cites] Scand J Gastroenterol. 1996 May;31(5):428-33 [8734337.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] Infect Immun. 1996 Jul;64(7):2829-33 [8698518.001]
  • [Cites] Infect Immun. 1990 Jun;58(6):1992-4 [2341188.001]
  • [Cites] Vet Parasitol. 1996 Apr;62(3-4):291-305 [8686175.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):951-7 [12615708.001]
  • [Cites] Infect Immun. 1999 Aug;67(8):4237-42 [10417197.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • (PMID = 15918071.001).
  • [ISSN] 0932-0113
  • [Journal-full-title] Parasitology research
  • [ISO-abbreviation] Parasitol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Helminth Proteins
  •  go-up   go-down


21. Kooyman FN, Ploeger HW, Höglund J, VAN Putten JP: Differential N-glycan- and protein-directed immune responses in Dictyocaulus viviparus-infected and vaccinated calves. Parasitology; 2007 Feb;134(Pt 2):269-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the search for protection-inducing antigens, we found that several D. viviparus third-stage larval (L3) and adult ES products carry N-glycans.
  • Challenge infection resulted in increased specific serum antibody levels against ES and L3 in the re-infected and challenge control groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17032477.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Immunodominant Epitopes; 0 / Polysaccharides
  •  go-up   go-down


22. Magrath IT: Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. Curr Hematol Malig Rep; 2006 Dec;1(4):230-40
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of Burkitt lymphoma in children and adults: Lessons from Africa.
  • Modern chemotherapy for childhood Burkitt lymphoma has its origins in Africa, where treatment evolved from one or two doses of single agents, which were curative in some patients, to combinations of non-cross-resistant drugs.
  • Therapy regimens for adults with Burkitt lymphoma have been developed by modifying second-generation pediatric protocols, and few investigators have used the third-generation pediatric regimens that include higher doses of methotrexate and additional agents.
  • Because childhood diffuse large-B-cell leukemia (DLBCL) responds equally well to therapy for Burkitt lymphoma, more intensive therapy and intensive support might also give better results in at least a subset of adults with advanced DLBCL-perhaps defined on the basis of limited molecular profiling, which has provided new information about the categories of aggressive B-cell lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy
  • [MeSH-minor] Adult. Age Factors. Anthracyclines / administration & dosage. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Central Nervous System / pathology. Child. Diagnosis, Differential. Drug Therapy / trends. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage. Randomized Controlled Trials as Topic / statistics & numerical data. Rituximab. Salvage Therapy. Treatment Outcome. Uganda / epidemiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425318.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 78
  •  go-up   go-down


23. Park YH, Kim WS, Kang HJ, Na II, Ryoo BY, Yang SH, Lee SS, Uhm JE, Kim K, Jung CW, Park K, Ko YH: Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol; 2006 May;85(5):285-90
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
  • Burkitt lymphoma/leukemia (BL) is a highly aggressive non-Hodgkin's lymphoma (NHL) often presenting in extranodal sites or as an acute leukemia.
  • Because of the shared molecular and genetic features, the World Health Organization classification of lymphoid diseases recognizes the lymphomatous and leukemic phases of BL as a single entity: a mature B cell neoplasm, subtype Burkitt lymphoma/Burkitt cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / mortality. Stomach Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518604.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Mossafa H, Damotte D, Jenabian A, Delarue R, Vincenneau A, Amouroux I, Jeandel R, Khoury E, Martelli JM, Samson T, Tapia S, Flandrin G, Troussard X: Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. Leuk Lymphoma; 2006 Sep;47(9):1885-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
  • Out of 344 patients with newly diagnosed non-Hodgkin's lymphoma (NHL), this study identified 16 patients presenting Burkitt-like cells (BLCs) after cytological and/or histological review.
  • These data could suggest a sub-group of NHL patients (15 B-NHL, 1 T-NHL) have been identified with a poor prognosis characterized by the association of Burkitt-like cells and c-MYC amplification without t(8;14)(q24;q32) or its variants.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Amplification. Lymphoma, T-Cell / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosomes, Human / genetics. Cytogenetic Analysis. Female. Humans. Immunoglobulin Heavy Chains / genetics. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Male. Middle Aged. Prognosis. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17065002.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


25. Song KW, Barnett MJ, Gascoyne RD, Horsman DE, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Voss NJ, Toze CL, Connors JM: Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol; 2006 Jun;133(6):634-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma.
  • High dose chemoradiotherapy and haematopoietic stem cell transplantation (SCT) is used as primary therapy for patients diagnosed with Burkitt lymphoma (BL).
  • [MeSH-major] Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16704438.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


26. Teitell MA, Lones MA, Perkins SL, Sanger WG, Cairo MS, Said JW: TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma. Am J Clin Pathol; 2005 Oct;124(4):569-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma.
  • Elevated T-cell leukemia-1 (TCL1) oncoprotein expression might promote human Burkitt lymphoma (BL) because increased TCL1 causes Burkitt-like lymphomas in TCL1 transgenic mice.
  • However, persistent EBV is not essential for increased TCL1 expression, although elevated TCL1 and c-MYC coexpression might cooperate in the development of most pediatric and adult BL cases.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoid Tissue / metabolism. Proto-Oncogene Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146820.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107300; United States / NCI NIH HHS / CA / R01 CA90571
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / RNA, Viral; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / TCL1A protein, human; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


27. Don TA, Oksov Y, Lustigman S, Loukas A: Saposin-like proteins from the intestine of the blood-feeding hookworm, Ancylostoma caninum. Parasitology; 2007 Mar;134(Pt 3):427-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both Ac-slp-1 and slp-2 mRNAs were shown to be expressed in all life stages assessed, with slp-1 predominantly being expressed in third-stage larvae (L3) before and after activation with dog serum.
  • These antisera were used as probes in fluorescence microscopy to localize the anatomic expression sites of both proteins to small, punctate organelles or vesicles within the intestinal cells of adult worms; weak staining was detected on the microvillar brush border of the intestine.
  • Using transmission electron microscopy, both proteins were localized to similar vesicles in the intestinal cells of the L3.
  • Their expression in the gut of the L3 and adult stages suggests a role for these hookworm SAPLIPs in the lysis of host cells during tissue migration and/or feeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17109779.001).
  • [ISSN] 0031-1820
  • [Journal-full-title] Parasitology
  • [ISO-abbreviation] Parasitology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Helminth Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Saposins
  •  go-up   go-down


28. McVeigh P, Leech S, Marks NJ, Geary TG, Maule AG: Gene expression and pharmacology of nematode NLP-12 neuropeptides. Int J Parasitol; 2006 May 31;36(6):633-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcription was also identified in both L3 and adult stages of T. colubriformis, in which Tc-nlp-12 is expressed in a single tail neurone.
  • Conversely, As-nlp-12 is expressed in both head and tail tissue of adult female A. suum, suggesting species-specific differences in the transcription pattern of this gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600246.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY347872/ DQ186899
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caenorhabditis elegans Proteins; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; 0 / Neuropeptides; 0 / aspartyl-tyrosyl-arginyl-prolyl-leucyl-glutaminyl-phenylalaninamide
  •  go-up   go-down


29. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ, Poppema S, van den Berg A: Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer; 2006 Feb;45(2):147-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma.
  • We previously demonstrated high expression of primary-microRNA BIC (pri-miR-155) in Hodgkin lymphoma (HL) and lack of expression in most non-Hodgkin lymphoma subtypes including some Burkitt lymphoma (BL) cases.
  • Recently, high expression of BIC was reported in BL in comparison to pediatric leukemia and normal peripheral-blood samples.
  • [MeSH-major] Burkitt Lymphoma / genetics. MicroRNAs / genetics
  • [MeSH-minor] Adolescent. Adult. Blotting, Northern. Cell Line, Tumor. Child. Child, Preschool. Genes, myc. Humans. Immunohistochemistry. In Situ Hybridization. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235244.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


30. Dixon H, Johnston CE, Else KJ: Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection. Parasite Immunol; 2008 Sep;30(9):454-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antigen selection for future anti-Trichuris vaccines: a comparison of cytokine and antibody responses to larval and adult antigen in a primary infection.
  • Subcutaneous vaccination with adult excretory-secretory products (ES) protects susceptible mouse strains from T. muris.
  • Larval stages may contain novel and more relevant antigens which when incorporated in a vaccine induce worm expulsion earlier in infection than the adult worm products.
  • This study finds negligible difference in the cellular and humoral immune response to T. muris adult and third stage larva(e) (L3) ES during a primary T. muris infection, but identifies high molecular weight proteins in both adult and L3 ES as potential vaccine candidates.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565148.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 068028
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antigens, Helminth; 0 / Cytokines; 0 / Immunoglobulin G; 0 / Vaccines
  •  go-up   go-down


31. Nomura S, Ishii K, Shimamoto Y, Yamamoto Y, Kadota E: Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier. Intern Med; 2006;45(4):215-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma of the uterus in a human T lymphotropic virus type-1 carrier.
  • A 71-year-old Japanese woman who was seropositive for T-lymphotropic virus type-1 (HTLV-1) developed primary Burkitt lymphoma of the uterus.
  • Biopsies from abdominal operation were diagnosed as Burkitt lymphoma.
  • Treatment was started with intensive chemotherapy according to a protocol for Burkitt lymphoma and mature-B cell leukemia.
  • [MeSH-major] Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / virology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16543692.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Kiss JE, Gao X, Krepp JM, Hawdon JM: Interaction of hookworm 14-3-3 with the forkhead transcription factor DAF-16 requires intact Akt phosphorylation sites. Parasit Vectors; 2009 Apr 24;2(1):21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Third-stage infective larvae (L3) of hookworms are in an obligatory state of developmental arrest that ends upon entering the definitive host, where they receive a signal that re-activates development.
  • Insulin-like signaling (ILS) mediates recovery from arrest in C. elegans and activation of hookworm dauer L3.
  • RESULTS: To determine if hookworm 14-3-3 proteins play a similar role in L3 activation, hookworm FTT-2 was identified and tested for its ability to interact with A. caninum DAF-16 in vitro.
  • Ac-FTT-2 was undetectable by Western blot in excretory/secretory products from serum-stimulated (activated) L3 or adult A. caninum.
  • CONCLUSION: The results indicate that Ac-FTT-2 interacts with DAF-16 in a phosphorylation-site dependent manner, and suggests that Ac-FTT-2 mediates activation of L3 by binding Ac-DAF-16 during hookworm infection.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vaccine. 2007 Jun 6;25(23):4533-9 [17485147.001]
  • [Cites] Dev Biol. 2007 Jan 1;301(1):82-91 [17098225.001]
  • [Cites] Int J Parasitol. 2005 Dec;35(14):1489-98 [16135366.001]
  • [Cites] Int J Parasitol. 2005 Mar;35(3):303-13 [15722082.001]
  • [Cites] Mech Ageing Dev. 2006 Sep;127(9):741-7 [16860373.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] Parasitology. 2006 Apr;132(Pt 4):535-43 [16388693.001]
  • [Cites] Sci STKE. 2005 Aug 9;2005(296):re10 [16091624.001]
  • [Cites] Adv Parasitol. 1963;1:109-77 [14117619.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Genes Dev. 1999 Jun 1;13(11):1438-52 [10364160.001]
  • [Cites] Mol Cell. 1998 Dec;2(6):887-93 [9885576.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2488-98 [9716402.001]
  • [Cites] Science. 1997 Aug 15;277(5328):942-6 [9252323.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):994-9 [9353126.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1319-22 [9360933.001]
  • [Cites] Nature. 1996 Aug 8;382(6591):536-9 [8700226.001]
  • [Cites] Curr Opin Genet Dev. 1996 Oct;6(5):618-23 [8939719.001]
  • [Cites] Mol Biochem Parasitol. 1996 Sep;80(1):113-7 [8885227.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Exp Parasitol. 1995 Mar;80(2):205-11 [7895832.001]
  • [Cites] Mol Biochem Parasitol. 1995 Jan;69(1):127-30 [7723782.001]
  • [Cites] Genetics. 1994 May;137(1):107-20 [8056303.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] Genes Dev. 1988 Oct;2(10):1277-83 [3203906.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5692 [3387244.001]
  • [Cites] J Parasitol. 1990 Jun;76(3):394-8 [2112598.001]
  • [Cites] Dev Biol. 1975 Oct;46(2):326-42 [1183723.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D423-6 [14681448.001]
  • [Cites] Protein Eng Des Sel. 2004 Jun;17(6):527-36 [15314210.001]
  • [Cites] Brief Bioinform. 2004 Jun;5(2):150-63 [15260895.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):3392-9 [15247332.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):329-42 [15167810.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] Nitric Oxide. 2004 May;10(3):150-5 [15158694.001]
  • [Cites] Int J Parasitol. 2004 Jun;34(7):873-80 [15157770.001]
  • [Cites] Biochemistry. 2003 Dec 30;42(51):15264-72 [14690436.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):575-81 [14642768.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36323-7 [12865427.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Int J Parasitol. 2003 Jul 30;33(8):787-93 [12865078.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3635-41 [12824383.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Vaccine. 2003 Jan 17;21(5-6):431-9 [12531641.001]
  • [Cites] Am J Trop Med Hyg. 2002 Mar;66(3):238-44 [12139214.001]
  • [Cites] Int J Parasitol. 2002 Jun;32(6):685-93 [12062487.001]
  • [Cites] Mol Biochem Parasitol. 2002 May;121(2):205-11 [12034454.001]
  • [Cites] J Parasitol. 2001 Aug;87(4):733-8 [11534634.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3061-4 [11709560.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13402-10 [11124266.001]
  • [Cites] Parasite Immunol. 2001 Apr;23(4):213-7 [11298298.001]
  • [Cites] Mol Cell Biol. 2001 May;21(10):3534-46 [11313479.001]
  • [Cites] FEBS Lett. 2001 Feb 9;490(1-2):65-9 [11172812.001]
  • [Cites] Parasite Immunol. 2000 Oct;22(10):521-8 [11012978.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):27-33 [10637628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):460-5 [10618440.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Int J Parasitol. 2009 Mar;39(4):407-15 [18930062.001]
  • [Cites] Biotechnol Adv. 2009 Mar-Apr;27(2):122-32 [18977428.001]
  • [Cites] Exp Parasitol. 2008 Aug;119(4):447-52 [18410929.001]
  • [Cites] Exp Parasitol. 2008 Aug;119(4):516-23 [18316081.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] Vaccine. 2007 Oct 10;25(41):7217-23 [17707955.001]
  • (PMID = 19393088.001).
  • [ISSN] 1756-3305
  • [Journal-full-title] Parasites & vectors
  • [ISO-abbreviation] Parasit Vectors
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI069293; United States / NIAID NIH HHS / AI / R01 AI069293-03; United States / NIAID NIH HHS / AI / R01 AI069293-01A1; United States / NIAID NIH HHS / AI / AI069293-02; United States / NIAID NIH HHS / AI / R21 AI062857; United States / NIAID NIH HHS / AI / AI069293-01A1; United States / NIAID NIH HHS / AI / AI069293-03; United States / NIAID NIH HHS / AI / R01 AI069293-02
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683825
  •  go-up   go-down


33. Wang Z, Abubucker S, Martin J, Wilson RK, Hawdon J, Mitreva M: Characterizing Ancylostoma caninum transcriptome and exploring nematode parasitic adaptation. BMC Genomics; 2010;11:307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The generated transcripts from four developmental stages, infective L3, serum stimulated L3, adult male and adult female, covered 93% of the A. caninum transcriptome.
  • Examining the developmental expression profiles of A. caninum revealed major transitions in gene expression from larval stages to adult.
  • Adult males expressed the highest number of selectively expressed genes, but adult female expressed the highest number of selective parasitism-related genes.
  • Parasitism related genes were expressed more selectively in adult male and female worms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2009;533:153-87 [19277558.001]
  • [Cites] BMC Genomics. 2009;10:22 [19144180.001]
  • [Cites] Nat Genet. 1999 Jul;22(3):231-8 [10391209.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1259-67 [15543149.001]
  • [Cites] BMC Bioinformatics. 2004 Nov 30;5:187 [15571632.001]
  • [Cites] BMC Genomics. 2005;6:58 [15854223.001]
  • [Cites] Infect Immun. 2006 Feb;74(2):961-7 [16428741.001]
  • [Cites] Lancet. 2006 May 6;367(9521):1521-32 [16679166.001]
  • [Cites] BMC Bioinformatics. 2007;8:41 [17284313.001]
  • [Cites] Science. 2007 Sep 21;317(5845):1756-60 [17885136.001]
  • [Cites] Clin Infect Dis. 2008 Jan 15;46(2):282-8 [18171264.001]
  • [Cites] Acta Trop. 1999 Oct 15;73(3):243-9 [10546842.001]
  • [Cites] Parasitol Today. 1999 May;15(5):188-93 [10322352.001]
  • [Cites] Nat Genet. 1999 Dec;23(4):452-6 [10581034.001]
  • [Cites] Int J Parasitol. 2000 Apr 10;30(4):347-55 [10731559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3029-33 [11248026.001]
  • [Cites] Bioinformatics. 2001 Sep;17(9):847-8 [11590104.001]
  • [Cites] Mol Biochem Parasitol. 2002 Mar;120(1):1-21 [11849701.001]
  • [Cites] Mol Biochem Parasitol. 2002 Apr 9;120(2):291-6 [11897134.001]
  • [Cites] Cell Mol Life Sci. 2002 Feb;59(2):349-62 [11915948.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1458-60 [12205047.001]
  • [Cites] J Parasitol. 2003 Apr;89(2):402-7 [12760667.001]
  • [Cites] Int J Parasitol. 2003 Aug;33(9):897-907 [12906874.001]
  • [Cites] Trends Parasitol. 2003 Dec;19(12):547-51 [14642761.001]
  • [Cites] J Mol Biol. 2004 May 14;338(5):1027-36 [15111065.001]
  • [Cites] Int J Parasitol. 2004 Jul;34(8):909-14 [15217729.001]
  • [Cites] J Parasitol. 1968 Jun;54(3):426-9 [5761146.001]
  • [Cites] Theor Popul Biol. 1975 Apr;7(2):256-76 [1145509.001]
  • [Cites] Annu Rev Physiol. 1981;43:323-41 [7011187.001]
  • [Cites] Mol Biol Evol. 1986 Sep;3(5):418-26 [3444411.001]
  • [Cites] J Parasitol. 1991 Aug;77(4):587-91 [1713962.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):6672-8 [8636085.001]
  • [Cites] Pediatr Res. 1996 Oct;40(4):515-21 [8888276.001]
  • [Cites] Nature. 1997 May 29;387(6632):489-93 [9168109.001]
  • [Cites] Biochem J. 1997 Jul 1;325 ( Pt 1):129-37 [9224638.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Nature. 1998 Mar 5;392(6671):71-5 [9510248.001]
  • [Cites] Genome Res. 1998 Jun;8(6):590-8 [9647634.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2012-8 [9851916.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2041-6 [9851921.001]
  • [Cites] Bioinformatics. 1998;14(9):755-63 [9918945.001]
  • [Cites] Mol Biochem Parasitol. 1999 Apr 30;99(2):149-65 [10340481.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Mol Biochem Parasitol. 2008 Feb;157(2):187-92 [18082904.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(1):e130 [18235850.001]
  • [Cites] PLoS Negl Trop Dis. 2008;2(10):e326 [18958170.001]
  • [Cites] Nat Rev Drug Discov. 2008 Nov;7(11):900-7 [18927591.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D571-8 [18940860.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):289-97 [19042974.001]
  • [Cites] BMC Evol Biol. 2009;9:23 [19175938.001]
  • [Cites] BMC Genomics. 2009;10:114 [19296854.001]
  • (PMID = 20470405.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vaccines
  • [Other-IDs] NLM/ PMC2882930
  •  go-up   go-down


34. Dávila C, Malagón D, Valero A, Benítez R, Adroher FJ: Anisakis simplex: CO(2)-fixing enzymes and development throughout the in vitro cultivation from third larval stage to adult. Exp Parasitol; 2006 Sep;114(1):10-5
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anisakis simplex: CO(2)-fixing enzymes and development throughout the in vitro cultivation from third larval stage to adult.
  • The results showed that a high pCO(2), at a suitable temperature, is vital for the optimum development of these nematodes, at least from the third larval stage (L3) to adult.
  • Throughout the development of the worms studied, PEPCK activity was much higher than that of PEPC (e.g., 305 vs. 6.8 nmol/min.mg protein, respectively, in L3 collected from the host fish).
  • The activity of these enzymes in the worms cultivated in air + 5% CO(2) was highest during M3, and was also generally higher than that of those cultivated in air only, especially during molting from L3 to L4 (e.g., in recently molted L4, PEPCK activity was 3.7 times greater than that of PEPC 2.9 times greater than when cultivated in air).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16600219.001).
  • [ISSN] 0014-4894
  • [Journal-full-title] Experimental parasitology
  • [ISO-abbreviation] Exp. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide; EC 4.1.1.31 / Phosphoenolpyruvate Carboxylase; EC 4.1.1.49 / Phosphoenolpyruvate Carboxykinase (ATP)
  •  go-up   go-down


35. Bricarello PA, Zaros LG, Coutinho LL, Rocha RA, Silva MB, Kooyman FN, De Vries E, Yatsuda AP, Amarante AF: Immunological responses and cytokine gene expression analysis to Cooperia punctata infections in resistant and susceptible Nelore cattle. Vet Parasitol; 2008 Aug 1;155(1-2):95-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum IgG1 mean levels against C. punctata antigens were higher in the resistant group, but significant differences between groups were only observed 14 days after the beginning of the experiment against infective larvae (L3) and 14 and 84 days against adult antigens.
  • The resistant group also presented higher IgA levels against C. punctata (L3 and adult) antigens with significant difference 14 days after the beginning of the trial (P<0.05).
  • In the small-intestine mucosa, levels of IgA anti-L3 and anti-adult C. punctata were higher in the resistant group, compared with the susceptible group (P<0.05).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18513872.001).
  • [ISSN] 0304-4017
  • [Journal-full-title] Veterinary parasitology
  • [ISO-abbreviation] Vet. Parasitol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Immunoglobulin A
  •  go-up   go-down


36. Queiroga EM, Gualco G, Chioato L, Harrington WJ, Araujo I, Weiss LM, Bacchi CE: Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8. Am J Clin Pathol; 2008 Aug;130(2):186-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral studies in burkitt lymphoma: association with Epstein-Barr virus but not HHV-8.
  • Burkitt lymphoma (BL) is a highly aggressive non-Hodgkin lymphoma, composed of a monomorphic population of medium-sized B cells with a high proliferation rate and a consistent MYC translocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Aug;19(8):1391-8 [15973450.001]
  • [Cites] J Exp Med. 2005 Aug 15;202(4):479-84 [16103407.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):834-7 [16136049.001]
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1039-45 [16189148.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):123-7 [16330952.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):23-31 [16360412.001]
  • [Cites] J Clin Invest. 2006 Mar;116(3):735-42 [16498502.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Acta Haematol. 2007;117(3):129-31 [17135725.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Br J Haematol. 2008 Jan;140(1):13-24 [17991301.001]
  • [Cites] Haematologica. 2005 Nov;90 Suppl:ECR35 [16266926.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1269-70 [10534180.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2130-6 [11264181.001]
  • [Cites] Clin Infect Dis. 2002 Feb 15;34(4):559-60 [11797191.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3415-8 [12384445.001]
  • [Cites] Br J Haematol. 2003 Feb;120(3):471-7 [12580962.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):66-70 [14618617.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Acta Otolaryngol. 2004 Apr;124(3):318-23 [15141762.001]
  • [Cites] J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 [2824665.001]
  • [Cites] Blood. 1992 Jun 15;79(12):3261-6 [1317726.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1396-403 [7858270.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Arch Dermatol. 1998 Jun;134(6):751 [9645650.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] J Cutan Pathol. 2005 Jan;32(1):21-7 [15660651.001]
  • [Cites] J Mol Diagn. 2005 Feb;7(1):17-27 [15681470.001]
  • [Cites] J Clin Pathol. 2005 Jun;58(6):626-8 [15917415.001]
  • (PMID = 18628086.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / 5R01CA082274; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / U01 CA121947-016821; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / R01 CA121935; United States / NCI NIH HHS / CA / CA121947-016821
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS125501; NLM/ PMC2718775
  •  go-up   go-down


37. Mary KA, Hoti SL, Paily KP: Monoclonal antibodies generated against excretory/secretory antigens of mammalian stage larvae of the lymphatic filarial parasite Wuchereria bancrofti. J Immunoassay Immunochem; 2007;28(4):343-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Five Mabs were obtained and, among them, Mab A7 showed high reactivity against e/s antigens of L4 and crude somatic antigens of microfilariae (mf) of W. bancrofti, and infective stage (L3) and adult stage larvae of Brugia malayi.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885888.001).
  • [ISSN] 1532-1819
  • [Journal-full-title] Journal of immunoassay & immunochemistry
  • [ISO-abbreviation] J Immunoassay Immunochem
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Antibodies, Monoclonal; 0 / Antigens, Helminth
  •  go-up   go-down


38. Nisbet AJ, Bell NE, McNeilly TN, Knox DP, Maizels RM, Meikle LI, Wildblood LA, Matthews JB: A macrophage migration inhibitory factor-like tautomerase from Teladorsagia circumcincta (Nematoda: Strongylida). Parasite Immunol; 2010 Jul;32(7):503-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A cDNA representing Tci-mif-1 was isolated following its identification in third-stage larvae (L3)-enriched cDNA population.
  • Messenger RNA (mRNA) representing the Tci-MIF-1 transcript was detected in eggs, L3 and adult stages of T. circumcincta.
  • Using immunohistochemistry, the Tci-MIF-1 protein was shown to have a diffuse distribution in L3 tissue, and in L4 and adult stages, the protein was localized to the nematode gut.
  • A recombinant version of Tci-MIF-1 was produced, and enzymic assays indicated that this recombinant protein and a somatic extract of L3 possessed dopachrome tautomerase activity as has been observed previously in other MIF-like molecules.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20591121.001).
  • [ISSN] 1365-3024
  • [Journal-full-title] Parasite immunology
  • [ISO-abbreviation] Parasite Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Helminth Proteins; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


39. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Burkitt lymphomas (BLs) still have poor outcome in patients with bone marrow (BM) or central nervous system (CNS) involvement when treated with standard-dose chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


40. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


41. Delaney A, Williamson A, Brand A, Ashcom J, Varghese G, Goud GN, Hawdon JM: Cloning and characterisation of an aspartyl protease inhibitor (API-1) from Ancylostoma hookworms. Int J Parasitol; 2005 Mar;35(3):303-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using sequence from the hookworm expressed sequence tag project, specific primers were designed and used to amplify Ac-api-1 from A. caninum infective L3 cDNA by PCR.
  • The A. ceylanicum api-1 cDNA of 878 bp was cloned from L3 cDNA using the A. caninum primers.
  • Ac-api-1 mRNA was detected by reverse transcriptase PCR in eggs, L1, L3 and adult life cycle stages.
  • A polyclonal antiserum against Escherichia coli expressed recombinant Ac-API-1 detected the protein in adult A. caninum excretory/secretory products, but not in those from activated infective larvae.
  • Immunolocalisation experiments using the antiserum indicated that Ac-API-1 is present primarily in the pseudocoelomic fluid in adult hookworms.
  • Soluble, yeast-expressed Ac-API-1 failed to inhibit pepsin or a hookworm gut aspartyl protease in vitro, but inhibited approximately 30% of the proteolytic activity of adult excretory/secretory products.
  • The pseudocoleomic location, presence in all life cycle stages, lack of inhibitory activity against pepsin, and inhibitory activity against excretory/secretory products suggest that Ac-API-1 inhibits an unidentified, putative aspartyl protease secreted by adult hookworms, and may be released as an enzyme-inhibitor complex.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15722082.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY705928/ AY705929
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / DNA, Complementary; 0 / DNA, Helminth; 0 / Protease Inhibitors; EC 3.4.23.- / Aspartic Acid Endopeptidases
  •  go-up   go-down


42. Iwata F, Shinjyo N, Amino H, Sakamoto K, Islam MK, Tsuji N, Kita K: Change of subunit composition of mitochondrial complex II (succinate-ubiquinone reductase/quinol-fumarate reductase) in Ascaris suum during the migration in the experimental host. Parasitol Int; 2008 Mar;57(1):54-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The flavoprotein (Fp) and small subunit of cytochrome b (CybS) in adult complex II differ from those of infective third stage larval (L3) complex II.
  • However, there is no difference in the iron-sulfur cluster (Ip) or the large subunit of cytochrome b (CybL) between adult and L3 isoforms of complex II.
  • In the present study, to clarify the changes that occur in the respiratory chain of A. suum larvae during their migration in the host, we examined enzymatic activity, quinone content and complex II subunit composition in mitochondria of lung stage L3 (LL3) A. suum larvae.
  • LL3 mitochondria showed higher QFR activity ( approximately 160 nmol/min/mg) than mitochondria of A. suum at other stages (L3: approximately 80 nmol/min/mg; adult: approximately 70 nmol/min/mg).
  • Interestingly, the results of two-dimensional bule-native/sodium dodecyl sulfate polyacrylamide gel electrophoresis analyses showed that LL3 mitochondria contained larval Fp (Fp(L)) and adult Fp (Fp(A)) at a ratio of 1:0.56, and that most LL3 CybS subunits were of the adult form (CybS(A)).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17933581.001).
  • [ISSN] 1383-5769
  • [Journal-full-title] Parasitology international
  • [ISO-abbreviation] Parasitol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Helminth; 0 / Protein Subunits; 0 / Quinones; EC 1.- / Oxidoreductases; EC 1.3.5.1 / Electron Transport Complex II; EC 1.3.99.- / quinol fumarate reductase
  •  go-up   go-down


43. Brand AM, Varghese G, Majewski W, Hawdon JM: Identification of a DAF-7 ortholog from the hookworm Ancylostoma caninum. Int J Parasitol; 2005 Dec;35(14):1489-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infective hookworm L3 encounter a host specific signal during invasion that re-activates suspended developmental pathways.
  • In the free-living nematode Caenorhabditis elegans, recovery from the developmentally arrested dauer stage in response to environmental cues is analogous to the resumption of development in invading hookworm L3.
  • An insulin-like signalling pathway mediates L3 activation in hookworms.
  • Sequence from a hookworm expressed sequence tag was used to design specific primers for PCR amplification of Ac-daf-7 from Ancylostoma caninum infective L3 cDNA.
  • Ac-daf-7 mRNA was strongly detected by reverse transcriptase PCR in L3 and serum stimulated L3 cDNA, and weakly in cDNA from L1 and adult life cycle stages.
  • Antiserum against Escherichia coli expressed recombinant Ac-DAF-7 detected the mature protein in L3 and adult soluble extracts, but not in excretory/secretory products from serum stimulated L3 or adults.
  • Increased expression in arrested L3 stages suggests that Ac-daf-7 is important for developmental arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135366.001).
  • [ISSN] 0020-7519
  • [Journal-full-title] International journal for parasitology
  • [ISO-abbreviation] Int. J. Parasitol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ DQ058687/ DQ059758
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Helminth; 0 / Caenorhabditis elegans Proteins; 0 / DAF-7 protein, C elegans; 0 / Transforming Growth Factor beta
  •  go-up   go-down


44. Lamvik J, Waage A, Wahl SG, Naess I, Paulsen PQ, Hammerstrøm J: Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004. Haematologica; 2006 Oct;91(10):1428-9
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute lymphoblastic leukemia, Burkitt's lymphoma and lymphoblastic lymphoma in middle Norway 1985-2004.
  • We report a population-based investigation on adult acute precursor B lymphoblastic leukemia, Burkitt's lymphoma and T lymphoblastic lymphoma in a defined geographic area.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Hematopoietic Stem Cells / pathology. Humans. Incidence. Male. Middle Aged. Norway / epidemiology


45. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


46. Gualco G, Queiroga EM, Weiss LM, Klumb CE, Harrington WJ Jr, Bacchi CE: Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma. Hum Pathol; 2009 Apr;40(4):565-71
Genetic Alliance. consumer health - Multiple myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent expression of multiple myeloma 1/interferon regulatory factor 4 in Burkitt lymphoma.
  • Burkitt lymphoma is a highly aggressive non-Hodgkin lymphoma with endemic, sporadic, and immunodeficiency-associated clinical variants composed of monomorphic medium-sized B cells with a high proliferation rate and a translocation involving the C-MYC locus.
  • Classically, the immunophenotype of Burkitt lymphoma has been considered to be the germinal center type.
  • In most reports, all cases of Burkitt lymphoma are reported to be multiple myeloma 1-negative. multiple myeloma 1 expression is seen in plasma cells and in a small fraction of B cells located in the light zone of germinal centers corresponding to the final step of intra-germinal center B-cell differentiation, and in activated T cells.
  • Twenty-five Burkitt lymphoma cases, including 19 associated with HIV, were reported in one of the few studies in the literature; 2 of these cases showed occasional multiple myeloma 1-positive cells, less than the 20% cutoff for positivity.
  • We studied 222 cases of well-characterized Burkitt lymphoma with the classic phenotype and C-MYC translocation and found 90 cases (40.5%) with multiple myeloma 1 nuclear expression, suggesting a late germinal center stage of differentiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] Am J Clin Pathol. 2008 Dec;130(6):946-56 [19019773.001]
  • [Cites] Leukemia. 2000 Apr;14(4):563-6 [10764139.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):247-57 [11091208.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):686-94 [11455001.001]
  • [Cites] Blood. 2002 Jan 15;99(2):409-26 [11781220.001]
  • [Cites] Br J Haematol. 2002 May;117(2):366-72 [11972519.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Leukemia. 1997 May;11(5):743-6 [9180301.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):293-312 [9620643.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):1-11 [9858526.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1031-6 [15840698.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):790-8 [16203284.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Oncologist. 2006 Apr;11(4):375-83 [16614233.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2495-8 [16760450.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):315-9 [16896892.001]
  • [Cites] Adv Anat Pathol. 2007 Jan;14(1):25-35 [17198308.001]
  • [Cites] Haematologica. 2007 Feb;92(2):267-8 [17296585.001]
  • [Cites] Am J Clin Pathol. 2007 Oct;128(4):558-64 [17875505.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1343-50 [17768115.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • [Cites] Leukemia. 2000 Mar;14(3):449-56 [10720141.001]
  • (PMID = 19144381.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112217; United States / NCI NIH HHS / CA / 5U01CA121947; United States / NCI NIH HHS / CA / CA121947-03; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / U01 CA121947-03; United States / NCI NIH HHS / CA / 5R01CA112217; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / 5R01CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; 0 / Interferon Regulatory Factors; 0 / Syndecan-1; 0 / interferon regulatory factor-4
  • [Other-IDs] NLM/ NIHMS125062; NLM/ PMC2741026
  •  go-up   go-down


47. Wang WM, Guan YG, Liu F, Wang TH, Xu XY, Ke Q, Lu YC, Yuan Y: [The influence of partial dorsal root rhizotomy on IGF-I expression in spared root ganglion and spinal cord]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jan;36(1):31-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To explore the temporospatial changes of IGF-I expression in the spared dorsal root ganglia (DRG, L6) on the operated side and un-operated side, in the spinal lamina II (L3, L5, L6) and Clarke's nucleus (L3) of the adult cats that have undergone partial dorsal rhizotomy, and compare them against those of the normal adult cats so as to unveil the relation between IGF-I and the plasticity of spinal cord.
  • METHODS: Fifteen male adult cats were divided into three groups.
  • The bilateral L6 dorsal root ganglia and L3, L5, L6 spinal cord of all groups were made into frozen sections 20 microm thick.
  • The distribution and the number of IGF-I positive neurons in bilateral spared DRG (L6) on the operated/un-operated side, in spinal lamina I (L3, L5, L6) and in Clarke' nucleus (L3) of each animal were observed and counted.
  • On the 14th day, the IGF-I expression in neurons of L6 DRG on the operated side was significantly lower than that of normal group and that of L6 spared DRG on the unoperated side (P<0.01), but it was not significantly different from that of the 7th day group (P>0.05). (2) There was no difference in number of IGF-I positive neuron in L3, L5, L6 spinal lamina II between normal group, 7th day post-operation group and 14th day post-operation group (P>0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702774.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


48. Davidsson J, Andersson A, Paulsson K, Heidenblad M, Isaksson M, Borg A, Heldrup J, Behrendtz M, Panagopoulos I, Fioretos T, Johansson B: Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet; 2007 Sep 15;16(18):2215-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3.
  • Although gain of 1q occurs in 25% of Burkitt lymphomas (BLs) and 10% of pediatric high hyperdiploid acute lymphoblastic leukemias (ALLs), little is known about the origin, molecular genetic characteristics and functional outcome of dup(1q) in these disorders.
  • [MeSH-major] Burkitt Lymphoma / genetics. Centromere / genetics. Chromosomes, Human, Pair 1 / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diploidy. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613536.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


49. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, Lyden ER, Heerema NA, Lones MA, Harrison L, Cairo MS, Sanger WG: An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol; 2010 Feb;148(4):600-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.
  • Burkitt lymphoma (BL), an aggressive B-cell malignancy, is often curable with short intensive treatment regiments.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 [7260888.001]
  • [Cites] N Engl J Med. 1997 Oct 30;337(18):1259-66 [9345074.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Ann Genet. 1989;32(1):26-32 [2751244.001]
  • [Cites] Cytogenet Cell Genet. 1989;52(3-4):136-8 [2630185.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Nov;1(2):115-8 [2487150.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):22-4 [1423221.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6547-52 [1330296.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Apr;6(4):199-205 [7685621.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):282-7 [7519050.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] Oncogene. 1997 Nov 13;15(20):2463-73 [9395242.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):1-19 [9720711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1084-92 [16862570.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2736-43 [17138821.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2773-80 [17132719.001]
  • [Cites] Br J Haematol. 2008 Jun;141(6):840-7 [18371107.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1925-30 [10706856.001]
  • [Cites] Blood Rev. 2001 Mar;15(1):49-59 [11333138.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):179-83 [12930318.001]
  • [Cites] Leukemia. 2003 Oct;17(10):2016-24 [14513052.001]
  • [Cites] Genes Chromosomes Cancer. 2004 May;40(1):10-8 [15034863.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Mar;26(3):169-78 [15125609.001]
  • [Cites] J Pathol. 2004 Aug;203(4):940-5 [15258997.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):965-9 [15291356.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1595-603 [15370211.001]
  • [Cites] Int J Cancer. 1977 Apr 15;19(4):482-6 [844916.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Leukemia. 2009 Feb;23(2):323-31 [19020548.001]
  • [Cites] Eur J Cancer. 1981 May;17(5):577-84 [6271555.001]
  • (PMID = 19895612.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS163764; NLM/ PMC2921871
  •  go-up   go-down


50. Boerma EG, Siebert R, Kluin PM, Baudis M: Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge. Leukemia; 2009 Feb;23(2):225-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.
  • Burkitt lymphoma (BL) has a characteristic clinical presentation, morphology, immunophenotype and primary chromosomal aberration, that is, the translocation t(8;14)(q24;q32) or its variants.
  • Within the core subset, no differences were found between pediatric and adult patients.
  • [MeSH-major] Burkitt Lymphoma / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923440.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 59
  •  go-up   go-down


51. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli MT, Guarini A, De Propris MS, Coustan-Smith E, Campana D, Foà R, Pizzolo G: Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica; 2006 Aug;91(8):1109-12
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.
  • A flow cytometric approach to minimal residual disease (MRD) monitoring useful in childhood B-lineage acute lymphoblastic leukemia (ALL) is discussed here in the context of ALL in adults.
  • Of 64 leukemia samples analyzed, 95.3% had at least one abnormal phenotype (57.3% had two or more) as compared to physiologic B-cell precursors in adult bone marrow.
  • Marker combinations for childhood ALL are also applicable to adult cases.
  • [MeSH-major] Burkitt Lymphoma / pathology. Flow Cytometry / methods. Neoplasm, Residual / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal. Antigens, CD / analysis. B-Lymphocytes / cytology. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Bone Marrow Cells / cytology. Bone Marrow Cells / pathology. Child. Fluorescein-5-isothiocyanate. Humans. Reference Values. Regeneration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885052.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


52. Chiaretti S, Li X, Gentleman R, Vitale A, Wang KS, Mandelli F, Foà R, Ritz J: Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res; 2005 Oct 15;11(20):7209-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation.
  • PURPOSE: To characterize gene expression signatures in acute lymphocytic leukemia (ALL) cells associated with known genotypic abnormalities in adult patients.
  • EXPERIMENTAL DESIGN: Gene expression profiles from 128 adult patients with newly diagnosed ALL were characterized using high-density oligonucleotide microarrays.
  • We also identified a set of 83 genes that were highly expressed in leukemia blasts from patients without known molecular abnormalities who subsequently relapsed following therapy.
  • CONCLUSIONS: Genomic signatures are associated with phenotypically and molecularly well defined subgroups of adult ALL.
  • Genomic profiling also identifies genes associated with poor outcome in cases without molecular aberrations and specific genes that may be new therapeutic targets in adult ALL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Leukemic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Cluster Analysis. Cytogenetic Analysis. Female. Flow Cytometry / methods. Humans. Immunophenotyping. Italy. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis / methods. Oncogene Proteins, Fusion / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243790.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA66996
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


53. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S, Sugahara K, Tsuruda K, Ishizaki A, Kamihira S: Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia; 2009 Nov;23(11):2090-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
  • Unfortunately, however, tumors including adult T-cell leukemia/lymphoma (ATL) have disadvantages such as p53 mutations and a lack of p16(INK4a) and/or p14(ARF).
  • In this study we characterized Nutlin-3a-induced cell death in 16 leukemia/lymphoma cell lines.
  • [MeSH-major] Apoptosis / drug effects. Imidazoles / pharmacology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Piperazines / pharmacology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / pathology. Cell Aging / drug effects. Cell Cycle / drug effects. Cell Line, Transformed. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Drug Synergism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Jurkat Cells. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. RNA, Small Interfering. TNF-Related Apoptosis-Inducing Ligand / pharmacology. Tumor Suppressor Protein p14ARF / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19710698.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C12orf5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Imidazoles; 0 / Intracellular Signaling Peptides and Proteins; 0 / Piperazines; 0 / RNA, Small Interfering; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


54. Burmeister T, Macleod RA, Reinhardt R, Mansmann V, Loddenkemper C, Marinets O, Drexler HG, Thiel E, Blau IW: A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement. Leuk Res; 2006 Nov;30(11):1417-23
Cellosaurus - a cell line knowledge resource. culture/stock collections - BLUE-1 (CVCL_1967) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique t(6;20)(q15;q11.2) rearrangement.
  • We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma.
  • Our findings are discussed in light of the current understanding of endemic and sporadic Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Line, Tumor. Chromosomes, Human, Pair 20 / genetics. Chromosomes, Human, Pair 6 / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Cytogenetic Analysis / methods. HLA Antigens / genetics. Histocompatibility Testing. Humans. Immunohistochemistry. Immunophenotyping. Male. Oligonucleotide Array Sequence Analysis / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697040.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


55. Primo D, Tabernero MD, Perez JJ, Rasillo A, Sayagués JM, Espinosa AB, Lopez-Berges MC, García-Sanz R, Gutierrez NC, Hernandez JM, Romero M, Osuna CS, Giralt M, Barbon M, San Miguel JF, Orfao A: Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics. Leukemia; 2005 May;19(5):713-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic heterogeneity of BCR/ABL+ adult B-cell precursor acute lymphoblastic leukemia: impact on the clinical, biological and immunophenotypical disease characteristics.
  • Philadelphia-positive (Ph(+)) B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a genetically heterogeneous disease with a very poor prognosis.
  • In this study, we analyzed the frequency of supernumerary Ph, trisomy 8, monosomy 7, and del(9p21) by FISH and its relationship with the characteristics of the disease, in 46 BCR/ABL(+) adult BCP-ALL patients.
  • [MeSH-major] Burkitt Lymphoma / genetics. Fusion Proteins, bcr-abl / genetics. Genetic Heterogeneity. Immunophenotyping
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. DNA / genetics. Disease-Free Survival. Female. Flow Cytometry / methods. Humans. In Situ Hybridization, Fluorescence / methods. Interphase. Karyotyping. Male. Middle Aged. Ploidies. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15789066.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


56. Pezzolo A, Cinti R, Negri F, Parodi F, Garaventa A, Gambini C, Pistoia V: Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors. Leuk Lymphoma; 2006 Nov;47(11):2359-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors.
  • This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published.
  • (2) imbalances already reported in adult but not in pediatric BLL cases and shared with most GC B-cell tumors (+7, -9p, -9q, +12q, -13q, +17, +19, -3 and -4);.
  • (3) imbalances already reported in pediatric but not in adult BLL cases and shared with some GC B-cell tumors (-2q); and (4) imbalances never described before in pediatric or adult BLL, but present in different GC B-cell tumors (-6p, -1p and -18q).
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Chromosomes, Human / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107910.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


57. Liu YR, Chen SS, Chang Y, Fu JY, Zhang LP, Wang H, Li LD, Zhu HH, Liu GL, Lu DP, Huang XJ: [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct;14(5):853-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
  • To evaluate the significance of FCM in minimal residual disease (MRD) detection, the immunophenotyping and leukemia-associated immunophenotypes (LAIP) of leukemia cells from 273 adult and 142 childhood patients with B lineage acute lymphoblastic leukemia (B-ALL) were detected by four to six antibody combinations of 4-color CD45/SSC gating multiparametric flow cytometry (FCM).
  • There was no significantce different for incidence of LAIP between adult and pediatric patients.
  • It is concluded that in 90% of childhood and adult B-ALL patients LAIP can be found, which suits MRD detection by multiparameter flow cytometry.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17096875.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


58. Aref S, Salama O, Shamaa S, El-Refaie M, Mourkos H: Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology; 2007 Aug;12(4):319-24
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia.
  • The angiogenic status and the exact role of the angiogenic cytokines in lymphoid leukemia has not been fully elucidated.
  • We have investigated the profile of the systemic components of angiogenic regulation in B-lineage acute lymphoblastic leukemia (B-ALL) and B-chronic lymphocytic leukemia (B-CLL), namely vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-alpha), endostatin and matrix metalloproteinase-9 (MMP-9) using enzyme-linked immunosorbent assay (ELISA).
  • A significant positive correlation between VEGF, TNF-alpha, MMP-9 and peripheral white cell counts, bone marrow lymphocytic count and platelets count were found.
  • In conclusion, our data suggest that the driving forces of angiogenic factors (VEGF, TNF-alpha and MMP-9) in adult B-ALL appears different from that in B-CLL patients.
  • [MeSH-major] Angiogenic Proteins / blood. Burkitt Lymphoma / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Neoplasm Proteins / blood
  • [MeSH-minor] Adolescent. Adult. Angiogenesis Inhibitors / blood. Blood Cell Count. Bone Marrow / pathology. Endostatins / blood. Enzyme-Linked Immunosorbent Assay. Female. Follow-Up Studies. Humans. Male. Matrix Metalloproteinase 9 / blood. Middle Aged. Neovascularization, Pathologic / blood. Tumor Necrosis Factor-alpha / analysis. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17654059.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Angiogenic Proteins; 0 / Endostatins; 0 / Neoplasm Proteins; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


59. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R: Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica; 2007 Mar;92(3):342-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
  • BACKGROUND AND OBJECTIVES: The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial.
  • The aim of this study was to correlate the expression of MyAg with clinical, hematologic and biological parameters, and to analyze the impact on response to treatment and prognosis in a large series of adult ALL uniformly characterized and treated.
  • DESIGN AND METHODS: We analyzed the expression of the MyAg CD13 and/or CD33 in a cohort of 377 adult patients with de novo ALL enrolled and treated in the GIMEMA ALL 0496 protocol.
  • RESULTS: MyAg expression was documented in 35% of the 377 adult ALL cases analyzed.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Cell Count. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / mortality. Burkitt Lymphoma / radiotherapy. Cell Lineage. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339183.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; EC 3.4.11.2 / Antigens, CD13; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


60. Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H: An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica; 2008 Nov;93(11):1734-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
  • In acute lymphoblastic leukemia, besides age and white cell count at diagnosis, the cytogenetic abnormalities t(9;22)/BCR-ABL and t(4;11)/MLL-AF4 are important prognostic markers and are often included in the treatment stratification of patients with adult acute lymphoblastic leukemia.
  • Deletions in 9p are seen in about 9% of cases of adult acute lymphoblastic leukemia, but their prognostic impact has been controversial.
  • Cytogenetic data from 381 patients diagnosed with B-precursor acute lymphoblastic leukemia were reviewed.
  • Our data suggest that chromosomal abnormalities involving 9p may have a significant negative impact on survival in adult B-precursor acute lymphoblastic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / mortality. Chromosomes, Human, Pair 9. Sequence Deletion
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Mapping. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 22. Genetic Markers. Humans. Karyotyping. Leukocyte Count. Middle Aged. Prognosis. Survival Analysis. Translocation, Genetic. World Health Organization

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728022.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


61. Song X, Gong S, Yang J, Wang J: Clinical and molecular cytogenetic characteristics of dic(9;20) in adult acute lymphoblastic leukemia: a case report of three patients. Ann Hematol; 2007 May;86(5):347-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular cytogenetic characteristics of dic(9;20) in adult acute lymphoblastic leukemia: a case report of three patients.
  • Dicentric (9;20) [dic(9;20)] is a rare recurring chromosome abnormality in leukemia patients.
  • In this study, we report three adult patients with acute lymphoblastic leukemia (ALL) with dic(9;20) anomaly.
  • All three patients were diagnosed as cluster of differentiation 10 (CD10) positive B cell ALL, achieved complete remission after induction chemotherapy, and died of leukemia relapse within 1 year after diagnosis.
  • The prognostic significance of dic(9;20) in adult patients with ALL remains to be determined.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 20. Chromosomes, Human, Pair 9. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245591.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Nelson BP, Treaba D, Goolsby C, Williams S, Dewald G, Gordon L, Peterson LC: Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum. Leuk Lymphoma; 2006 Jul;47(7):1352-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum.
  • Precursor B-lymphoblastic leukemia is typically surface immunoglobulin (sIg) negative.
  • Although rare cases of sIg+ precursor lymphoblastic leukemia are recognized, sIg+ leukemia often represent leukemic phase of Burkitt lymphoma or other non-Hodgkin lymphoma such as blastic mantle cell lymphoma.
  • This study reports four adults, two women (56 and 58 years old) and two men (35 and 41 years old) with lymphoblastic leukemia that displayed lambda, surface immunoglobulin restriction (sIg+).
  • Genetic abnormalities were detected in all cases and in three cases included abnormalities commonly present in precursor lymphoblastic leukemia.
  • Deletion of the 3' region of the mixed lineage leukemia (MLL) gene at chromosome 11q23 as well as t(14;18) were detected in the second case.
  • Deletion of the 3' region of the mixed lineage leukemia (MLL) gene at chromosome 11q23 as well as t(14;18) were detected in one case.
  • These cases illustrate that lymphoblastic leukemias occurring in adults exhibit a morphologic, immunophenotypic as well as a genetic spectrum and represent either non-Hodgkin lymphoma or precursor lymphoblastic leukemia.
  • [MeSH-major] Immunoglobulins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Translocation, Genetic
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / metabolism. Burkitt Lymphoma / metabolism. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping / methods. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16923568.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


63. Matsuno N, Hoshino K, Nanri T, Kawakita T, Suzushima H, Kawano F, Mitsuya H, Asou N: p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia. Leuk Res; 2005 May;29(5):557-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p15 mRNA expression detected by real-time quantitative reverse transcriptase-polymerase chain reaction correlates with the methylation density of the gene in adult acute leukemia.
  • Cyclin-dependent kinase inhibitor p15 is frequently inactivated by either methylation or deletion in patients with acute leukemia.
  • To examine pathologic and clinical significance of the p15 gene inactivation, we established a quantitative assay of p15 mRNA expression in the bone marrow cells by real-time quantitative reverse transcriptase-polymerase chain reaction. p15 mRNA expression in 14 patients with precursor B-cell acute lymphoblastic leukemia (PBC-ALL) well correlated with status of deletion and methylation in the p15 gene analyzed by Southern blotting.
  • Furthermore, two patients with PBC-ALL and 11 acute myeloblastic leukemia (AML) were quantitatively examined for p15 gene methylation using bisulfite genomic sequencing.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. DNA Methylation. Gene Expression Regulation, Leukemic. Leukemia, Myeloid / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Messenger / metabolism. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Acute Disease. Adult. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Lineage. CpG Islands. Cyclin-Dependent Kinase Inhibitor p15. Humans. Reverse Transcriptase Polymerase Chain Reaction. Sequence Deletion. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755508.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN2B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


64. Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, Willman CL, Heimfeld S, Boldt DH, Radich JP: Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood; 2007 Apr 1;109(7):3080-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia.
  • We compared the gene expression profile of adult acute lymphoblastic leukemia (ALL) to normal hematopoietic and non-ALL samples using oligonucleotide arrays.
  • CTGF expression was examined by quantitative reverse transcriptase-polymerase chain reaction (ORT-PCR) on 79 adult ALL specimens.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Mol Biol Cell. 1993 Jun;4(6):637-45 [8374172.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):781-91 [15613452.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55958-68 [15496414.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7209-19 [16243790.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2072-81 [15041728.001]
  • [Cites] J Cell Physiol. 2000 Jan;182(1):119-26 [10567923.001]
  • [Cites] Br J Cancer. 2000 Sep;83(6):756-60 [10952780.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] Mol Pathol. 2002 Feb;55(1):40-5 [11836446.001]
  • [Cites] Development. 2003 Jun;130(12):2779-91 [12736220.001]
  • [Cites] Development. 2004 May;131(9):2137-47 [15105373.001]
  • [Cites] World J Surg. 2004 Aug;28(8):818-25 [15457365.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12981-6 [9371786.001]
  • (PMID = 17170128.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA018029; United States / NCI NIH HHS / CA / CA114762; United States / NCI NIH HHS / CA / CA18029; United States / NCI NIH HHS / CA / CA32102
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTGF protein, human; 0 / DNA Primers; 0 / Immediate-Early Proteins; 0 / Intercellular Signaling Peptides and Proteins; 139568-91-5 / Connective Tissue Growth Factor
  • [Other-IDs] NLM/ PMC1852221
  •  go-up   go-down


65. Ravandi F, Faderl S, Kebriaei P, Kantarjian H: Modern treatment programs for adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2007 Jul;2(3):169-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modern treatment programs for adults with acute lymphoblastic leukemia.
  • The current treatment programs for adult patients with acute lymphoblastic leukemia are modeled on pediatric regimens.
  • The result has been complete remission rates comparable to those seen in children, but a significant proportion of adult patients relapse.
  • Salvage therapy for patients with acute lymphoblastic leukemia continues to have limited success.
  • The development of techniques for identification and monitoring of minimal residual leukemia has provided possible ways to predict relapse and consider early intervention.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Central Nervous System / pathology. Clinical Trials as Topic / statistics & numerical data. Combined Modality Therapy. Cranial Irradiation. Female. Humans. Leukemic Infiltration / prevention & control. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Philadelphia Chromosome. Protein Kinase Inhibitors / therapeutic use. Remission Induction. Salvage Therapy. Stem Cell Transplantation. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425366.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 69
  •  go-up   go-down


66. Wu JM, Georgy MF, Burroughs FH, Weir EG, Rosenthal DL, Ali SZ: Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone? Diagn Cytopathol; 2009 Nov;37(11):820-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma, leukemia, and pleiocytosis in cerebrospinal fluid: is accurate cytopathologic diagnosis possible based on morphology alone?
  • The spectrum of disease ranged from acute myeloid leukemia, mantle cell lymphoma, chronic lymphocytic lymphoma, Burkitt lymphoma, large cell lymphoma, T cell lymphoma, and non-Hodgkin lymphoma.
  • Of the malignant cases, there was a higher proportion of correct diagnosis based on morphology in the acute malignancies (67%) versus the chronic malignancies (47%).
  • [MeSH-major] Flow Cytometry. Leukemia / cerebrospinal fluid. Leukemia / diagnosis. Lymphoma / cerebrospinal fluid. Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cytological Techniques. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526571.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Song JH, Schnittke N, Zaat A, Walsh CS, Miller CW: FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. Leuk Res; 2008 Nov;32(11):1751-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
  • Mutations of FBXW7 have been found in human colorectal, ovarian, endometrial tumors and T-cell acute lymphocytic leukemias.
  • Prompted by these findings we have examined acute myeloid leukemia, non-Hodgkin's lymphoma, T-cell acute lymphocytic leukemia, B-cell acute lymphocytic leukemia and adult T-cell leukemia DNA for mutations of the FBXW7 gene.
  • As expected, mutations were found in T-cell acute lymphocytic leukemias.
  • However mutations of FBXW7 were also found in four of 118 B-cell acute lymphocytic leukemias and one of 24 adult T-cell leukemia samples.
  • These observations suggest that disruption of FBXW7 has a role in several forms of lymphocytic leukemias and not exclusively T-cell acute lymphocytic leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, Non-Hodgkin / genetics. Mutation / genetics. Ubiquitin-Protein Ligases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485478.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; EC 6.3.2.19 / FBXW7 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


68. Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I: WT1 protein expression in childhood acute leukemia. Am J Hematol; 2008 May;83(5):382-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 protein expression in childhood acute leukemia.
  • In patients with acute leukemia, Wilms' tumor gene 1 (WT1) has been used as a target for the detection of minimal residual disease (MRD) by PCR techniques.
  • To determine the relation between expression of WT1 transcripts and of the encoded protein, we examined leukemic cell lines and primary childhood leukemia samples using both real-time quantitative PCR (RQ-PCR) and flow cytometry.
  • By contrast, 40 primary samples of acute lymphoblastic leukemia (ALL; B-ALL, n = 15 and T-ALL, n = 10) and acute myeloid leukemia (n = 15) expressed low levels of WT1 protein.
  • RQ-PCR detected WT1 transcript levels in the same range as reported in earlier studies in childhood acute leukemia.
  • (ii) WT1 is not a suitable marker for flow cytometric MRD detection in childhood acute leukemia.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Neoplasm Proteins / analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. WT1 Proteins / analysis
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Blood Cells / metabolism. Bone Marrow Cells / metabolism. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / metabolism. Child. Child, Preschool. Female. Flow Cytometry. Genes, Wilms Tumor. Humans. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Male. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18161786.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  •  go-up   go-down


69. Chen W, Karandikar NJ, McKenna RW, Kroft SH: Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience. Am J Clin Pathol; 2007 Jan;127(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: a single institution experience.
  • Essentially all cases of precursor B-lymphoblastic leukemia/lymphoma (B-ALL) demonstrate multiple immunophenotypic aberrancies relative to normal maturing B-cell precursors (hematogones).
  • We compared the immunophenotypes at diagnosis and relapse in 51 childhood and adult B-ALLs with flow cytometry (FC) using broad antibody panels.
  • [MeSH-major] B-Lymphocytes / cytology. Burkitt Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / analysis. Female. Flow Cytometry / methods. Follow-Up Studies. Humans. Immunophenotyping / methods. Infant. Male. Middle Aged. Recurrence. Retrospective Studies

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145625.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


70. Sancho JM, Ribera JM, Oriol A, Hernandez-Rivas JM, Rivas C, Bethencourt C, Parody R, Deben G, Bello JL, Feliu E, Programa para el Estudio y Tratamiento de Hemopatias Malignas Group: Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer; 2006 Jun 15;106(12):2540-6
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
  • Recurrence of acute lymphoblastic leukemia (ALL) in the central nervous system (CNS) confers a poor prognosis, although to the authors' knowledge, only a few studies have analyzed this issue in adults.
  • For the current study, the authors analyzed the frequency, predictive factors, and prognosis of CNS involvement and recurrence in adult patients with ALL who did not receive cranial irradiation for CNS prophylaxis.
  • Four hundred sixty-seven adult patients (age > or = 15 years) with ALL were treated on 4 protocols: ALL-89 (standard-risk and high-risk ALL; n = 108 patients), ALL-93 (high-risk ALL; n = 222 patients), ALL-96 (standard-risk ALL; n = 84 patients), and ALL3-97 (Burkitt leukemia; n = 53 patients).
  • The frequency of CNS recurrence in adult patients with ALL who do not receive radiotherapy for CNS prophylaxis was similar to the frequency observed in protocols that included cranial irradiation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Female. Humans. Hydrocortisone / administration & dosage. Incidence. Lactate Dehydrogenases / analysis. Male. Methotrexate / administration & dosage. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16700036.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 1.1.- / Lactate Dehydrogenases; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


71. Jakab K, Gopcsa L, Adam E, Domjan G, Sarkadi B, Paloczi K: Application of flow cytometry immunophenotyping and multidrug resistance assay in B-cell acute lymphoid leukemia and multiple myeloma. Neoplasma; 2005;52(1):36-42
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of flow cytometry immunophenotyping and multidrug resistance assay in B-cell acute lymphoid leukemia and multiple myeloma.
  • In this study we aimed to evaluate and compare the drug resistance in B-cell acute lymphoid leukemia (B-ALL) and multiple myeloma (MM) in association with their immunophenotypes and genotypes.
  • However, the mean MRP-1 values in MM were significantly lower than MAF-MDR-1 (1.85+/-3.8 versus 5.92+/-7.45, p=0.05), but we have found lower values in refractory conditions as expected from previous studies of acute myeloid leukemia.
  • [MeSH-major] Biomarkers, Tumor / analysis. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Drug Resistance, Multiple. Multiple Myeloma / drug therapy. Multiple Myeloma / genetics
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / analysis. Female. Flow Cytometry. Genotype. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739024.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, Dastugue N, Brousset P: A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood; 2007 Apr 15;109(8):3417-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
  • We report a novel t(7;9)(q11;p13) translocation in 2 patients with B-cell acute lymphoblastic leukemia (B-ALL).
  • After cloning the full-length cDNA of the chimeric gene, confocal microscopy of transfected NIH3T3 cells and Burkitt lymphoma cells (DG75) demonstrated that PAX5-ELN was localized in the nucleus.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Elastin / genetics. Genes, Dominant. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Animals. Antigens, CD19 / biosynthesis. Antigens, CD19 / genetics. Cell Differentiation / genetics. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. HeLa Cells. Humans. Male. Mice. NIH 3T3 Cells. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179230.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 9007-58-3 / Elastin
  •  go-up   go-down


73. Stachel D, Albert M, Meilbeck R, Paulides M, Schmid I: Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep; 2007 Jan;17(1):147-52
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia.
  • Vascular endothelial growth factor (VEGF) seems to play a central role in tumor angiogenesis and is associated with a poor prognosis in both solid tumors and adult leukemias.
  • In pediatric acute lymphocytic leukemia however, the expression of angiogenic molecules and its relation to prognosis and relapse are unknown.
  • Therefore, we prospectively analyzed 46 pediatric patients with precursor B cell acute lymphocytic leukemia by semi-quantitative RT-PCR for expression of the angiogenic molecules VEGF, VEGF-C, iNOS and TGF-beta and correlated relapse and survival data with the expression of these factors.
  • The mRNA expression of iNOS in the surviving children possibly reflects an increased activity of the immune system against the leukemia which leads to a superior survival.
  • [MeSH-major] Angiogenic Proteins / biosynthesis. Burkitt Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143492.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Angiogenic Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


74. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M: Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia; 2007 Apr;21(4):697-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients.
  • As histopathogenesis is relevant for B-cell chronic lymphocytic leukemia (B-CLL) prognosis, TRF-L was assessed by Southern blot in 201 patients and compared to variable immunoglobulin heave chain gene mutational status (VH-MS) and to other known prognostic features.
  • [MeSH-major] Burkitt Lymphoma / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Telomere / ultrastructure
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Allelic Imbalance. Disease-Free Survival. Humans. Immunoglobulin Variable Region. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis


75. Gijzen K, Raymakers RA, Broers KM, Figdor CG, Torensma R: Interaction of acute lymphopblastic leukemia cells with C-type lectins DC-SIGN and L-SIGN. Exp Hematol; 2008 Jul;36(7):860-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interaction of acute lymphopblastic leukemia cells with C-type lectins DC-SIGN and L-SIGN.
  • In acute lymphoblastic leukemia (ALL), aberrant glycosylation of blast cells can alter their interaction with the C-type lectins DC-SIGN and L-SIGN, thereby affecting their immunological elimination.
  • [MeSH-major] Burkitt Lymphoma / immunology. Cell Adhesion Molecules / immunology. Dendritic Cells / immunology. Immune Tolerance. Lectins, C-Type / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. Receptors, Cell Surface / immunology
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Carbohydrates / immunology. Child. Child, Preschool. Disease-Free Survival. Endothelial Cells / immunology. Endothelial Cells / pathology. Female. Glycosylation. Humans. Liver / immunology. Liver / pathology. Male. Middle Aged. Protein Binding / immunology. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375037.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CLEC4M protein, human; 0 / Carbohydrates; 0 / Cell Adhesion Molecules; 0 / DC-specific ICAM-3 grabbing nonintegrin; 0 / Lectins, C-Type; 0 / Receptors, Cell Surface
  •  go-up   go-down


76. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.
  • Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another hematologic disorder (acute leukemia) highlights increased sHLA-G secretion.
  • This increased secretion seems more marked in acute leukemia subtypes affecting monocytic and lymphoid lineages such as FABM4 and FABM5, as well as both B and T acute lymphoblastic leukemia (ALL).
  • All these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during acute leukemia.
  • [MeSH-major] Antigens, Neoplasm / blood. HLA Antigens / blood. Histocompatibility Antigens Class I / blood. Leukemia / blood
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


77. Landau H, Lamanna N: Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep; 2006 Sep;1(3):171-9
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.
  • Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups.
  • Although there has been marked improvement in the outcomes for pediatric patients with ALL, the same success has not yet been realized for adult patients.
  • This article reviews the classification, prognostic features, current treatment programs, and new advances as applied to adult patients with newly diagnosed ALL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / classification. Burkitt Lymphoma / therapy. Central Nervous System / pathology. Child. Clinical Trials as Topic. Cranial Irradiation. Eye / pathology. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Incidence. Leukemic Infiltration / drug therapy. Leukemic Infiltration / prevention & control. Leukemic Infiltration / radiotherapy. Lymphocyte Subsets / pathology. Male. Neoplasm, Residual. Prognosis. Remission Induction. Testis / pathology. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425348.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


78. Strefford JC, Worley H, Barber K, Wright S, Stewart AR, Robinson HM, Bettney G, van Delft FW, Atherton MG, Davies T, Griffiths M, Hing S, Ross FM, Talley P, Saha V, Moorman AV, Harrison CJ: Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization. Oncogene; 2007 Jun 21;26(29):4306-18
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome complexity in acute lymphoblastic leukemia is revealed by array-based comparative genomic hybridization.
  • Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL).
  • However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Profiling. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics. Nucleic Acid Hybridization. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Gene Dosage. Humans. Infant. Male. Middle Aged. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237825.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Guillaume N, Alleaume C, Munfus D, Capiod JC, Touati G, Pautard B, Desablens B, Lefrère JJ, Gouilleux F, Lassoued K, Gouilleux-Gruart V: ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica; 2005 Jul;90(7):899-905
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
  • While little is known about ZAP-70 expression in normal human B cells, it has been reported that ZAP-70 is expressed in a subset of patients with chronic lymphocytic leukemia (CLL) with a poor prognosis.
  • In this study, we examined the expression and phosphorylation status of ZAP-70 in B-lineage acute lymphoblastic leukemia (Blin-ALL).
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Gene Expression Regulation, Neoplastic. ZAP-70 Protein-Tyrosine Kinase / biosynthesis. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Bone Marrow / metabolism. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Phosphorylation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Jul;90(7):867 [15996917.001]
  • (PMID = 15996927.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


80. Olsnes AM, Motorin D, Ryningen A, Zaritskey AY, Bruserud Ø: T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC). Cancer Immunol Immunother; 2006 Jul;55(7):830-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).
  • T cell targeting immunotherapy is now considered in acute myelogenous leukemia (AML), and local recruitment of antileukemic T cells to the AML microcompartment will then be essential.
  • [MeSH-major] Chemokines, CC / secretion. Chemokines, CXC / secretion. Chemotaxis, Leukocyte. Leukemia, Myeloid / physiopathology. Neoplasm Proteins / secretion. Neoplastic Stem Cells / secretion
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / physiopathology. Cell Communication. Chemokine CCL17. Chemokine CCL5. Chemokine CXCL10. Coculture Techniques. Culture Media, Conditioned / chemistry. Female. Fibroblasts / physiology. Humans. Infection / complications. Infection / physiopathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Male. Middle Aged. Osteoblasts / secretion. RNA, Messenger / analysis. Stromal Cells / physiology. T-Lymphocytes / immunology. Tumor Cells, Cultured / secretion

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16267679.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CCL17 protein, human; 0 / CCL5 protein, human; 0 / CXCL10 protein, human; 0 / Chemokine CCL17; 0 / Chemokine CCL5; 0 / Chemokine CXCL10; 0 / Chemokines, CC; 0 / Chemokines, CXC; 0 / Culture Media, Conditioned; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


81. Hallböök H, Gustafsson G, Smedmyr B, Söderhäll S, Heyman M, Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group: Treatment outcome in young adults and children &gt;10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer; 2006 Oct 1;107(7):1551-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol.
  • BACKGROUND: Several studies have reported a more favorable outcome for teenagers and young adults with acute lymphoblastic leukemia (ALL) when they were treated in pediatric oncology departments compared with adult hematology departments.
  • METHODS: In Sweden during the 1990s, adolescents with ALL were treated in a pediatric oncology unit or in an adult hematologic unit, depending on the initial referral.
  • In the current national, comparative, retrospective study, patients with ALL aged 10 years to 40 years who were treated either according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL protocol (1992-2000) (NOPHO-92 protocol) or according to the Swedish Adult ALL Group protocol (1994-2000) (Adult protocol) were included.
  • There was a significant difference in the remission rate between the NOPHO-92 protocol (99%; n = 144 patients) and the Adult protocol (90%; n = 99 patients; P < .01), and the event-free survival (EFS) was also superior for the NOPHO-92 protocol compared with the Adult protocol (P < .01).
  • However, EFS was higher for patients aged 15 years to 25 years compared with patients aged 26 years to 40 years within the Adult protocol group (P = .01).
  • CONCLUSIONS: The NOPHO-92 protocol resulted in a better outcome than the Adult protocol; therefore, adolescents may benefit from the pediatric protocol treatment strategy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Prognosis. Survival Analysis. Sweden. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16955505.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


82. Babusíková O, Zelezníková T, Mlcáková A, Kusenda J, Stevulová L: The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia. Neoplasma; 2005;52(6):502-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
  • Increased information on benign B-lymphocyte precursors, especially that of existence of the 3rd type hematogones could provide a basis for better discrimination of B-leukemia cells even in a very small amounts.
  • [MeSH-major] Antigens, CD / analysis. B-Lymphocytes / immunology. Bone Marrow / immunology. Bone Marrow Cells / cytology. Burkitt Lymphoma / diagnosis. Immunophenotyping
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Middle Aged. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284697.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


83. Crespo M, Villamor N, Giné E, Muntañola A, Colomer D, Marafioti T, Jones M, Camós M, Campo E, Montserrat E, Bosch F: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 Feb 1;12(3 Pt 1):726-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
  • The purpose was to investigate the presence of ZAP-70 in normal pro/pre B cells and mature B cells and in tumoral cells from B-acute lymphoblastic leukemias (B-ALL).
  • Among tumoral cells, ZAP-70 was expressed in 56% of B-ALLs with pro/pre B-cell phenotype and in 4 of 6 Burkitt/ALL lymphomas.
  • The lack of ZAP-70 expression in normal mature B cells suggests that its expression in mature-derived neoplasms with different cellular origin, such as Burkitt's lymphoma and chronic lymphocytic leukemia, might be due to an aberrant phenomenon.
  • [MeSH-major] B-Lymphocytes / metabolism. Burkitt Lymphoma / genetics. Gene Expression Regulation. Gene Expression Regulation, Leukemic. Hematopoietic Stem Cells / metabolism. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Mutational Analysis. Humans. Middle Aged. Phenotype. Phosphorylation. Receptors, Antigen, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16467082.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


84. Meyer-Monard S, Parlier V, Passweg J, Mühlematter D, Hess U, Bargetzi M, Kühne T, Cabrol C, Gratwohl A, Jotterand M, Tichelli A: Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia. Leukemia; 2006 Feb;20(2):247-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of broad molecular screening and cytogenetic analysis for genetic risk assignment and diagnosis in patients with acute leukemia.
  • We evaluated the impact of genetic analysis combining cytogenetics and broad molecular screening on leukemia diagnosis according to World Health Organization (WHO) and on genetic risk assignment.
  • Broad molecular screening and cytogenetics are complementary in the diagnosis and genetic risk assignment of acute leukemia.
  • [MeSH-major] Burkitt Lymphoma / genetics. Cytogenetic Analysis / methods. Leukemia, Myeloid / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Molecular Diagnostic Techniques / methods. Myelodysplastic Syndromes / genetics. Neoplasms, Second Primary / genetics
  • [MeSH-minor] Acute Disease. Adult. Child. Chromosome Aberrations. Cohort Studies. Female. Humans. Karyotyping. Male. Prospective Studies. Reverse Transcriptase Polymerase Chain Reaction / methods. Risk Assessment. World Health Organization

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408102.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


85. Kataoka K, Seo S, Sugawara Y, Ota S, Imai Y, Takahashi T, Fukayama M, Kokudo N, Kurokawa M: Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. Leuk Lymphoma; 2010 Aug;51(8):1494-501
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature.
  • We investigated 323 consecutive patients undergoing adult-to-adult LDLT and identified three patients who developed biopsy-proven PTLD.
  • All three patients developed late-onset and monomorphic PTLD, including one diffuse large B-cell lymphoma and two Burkitt lymphomas with c-myc rearrangement.
  • We showed a relatively low incidence and distinct clinicopathological features of PTLD after adult-to-adult LDLT, which might reflect the unique nature of LDLT.
  • [MeSH-minor] Adolescent. Adult. Aged. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / isolation & purification. Humans. Male. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Review Literature as Topic. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Aug;51(8):1393-4 [20497000.001]
  • (PMID = 20578817.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T: CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol; 2007 Sep 1;179(5):2880-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.
  • In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-cell acute lymphocytic leukemia (B-ALL) CD23+CD5+ B cells.
  • [MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD5 / analysis. Child. Child, Preschool. Cytotoxicity, Immunologic. Female. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Proteins / antagonists & inhibitors. Proteins / genetics. Proteins / metabolism. RNA, Small Interfering / pharmacology. Receptors, IgE / analysis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2007 Nov 15;179(10):7184
  • (PMID = 17709502.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10
  •  go-up   go-down


87. Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF: Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant; 2006 Aug;38(3):203-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.
  • We explored the safety and efficacy of rituximab administered in combination with the standard transplant conditioning regimen of cyclophosphamide (Cy) 120 mg/kg and total body irradiation (TBI) 12 Gy for adult patients with acute lymphoblastic leukemia (ALL).
  • The cumulative incidence of grade II-IV acute GVHD was 17%, and limited and extensive chronic GVHD was 43% at 2 years.
  • The addition of rituximab to the standard Cy/TBI transplant conditioning regimen in ALL was safe and well tolerated, and there was a suggestion of decreased incidence of acute GVHD when compared to historically reported GVHD rates for this group of patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / therapy. Graft vs Host Disease / prevention & control. Immunologic Factors / therapeutic use. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning / methods
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Chi-Square Distribution. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Middle Aged. Rituximab. Statistics, Nonparametric. Survival Analysis. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799614.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


88. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


89. Lin RF, Li JY, Lu H, Wu YJ, Qiu HR, Xiao B, Zhang JF, Yang H: [Bone marrow necrosis as an initial manifestation of Philadelphia chromosome and myeloid antigens positive B acute lymphoblastic leukemia--a case report]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):832-4
Genetic Alliance. consumer health - Bone marrow necrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone marrow necrosis as an initial manifestation of Philadelphia chromosome and myeloid antigens positive B acute lymphoblastic leukemia--a case report].
  • Many diseases cause bone marrow necrosis (BMN), especially lymphocytic leukemia.
  • To explore the complexity of the pathogenesis and pathology of BMN and understand the multiplicity of clinical features, a case of Philadelphia chromosome positive (Ph+) B acute lymphoblastic leukemia (ALL) expressing myeloid antigens was reported.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928333.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


90. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, Choi JK, Houghton PJ, Brown VI, Grupp SA: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood; 2006 Feb 1;107(3):1149-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
  • Acute lymphoblastic leukemia (ALL) in adult patients is often resistant to current therapy, making the development of novel therapeutic agents paramount.
  • Lymphoblasts from adult patients with precursor B ALL were cultured on bone marrow stroma and were treated with CCI-779, a second generation MTI.
  • We conclude that MTIs can inhibit the growth of adult human ALL and deserve close examination as therapeutic agents against a disease that is often not curable with current therapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antibiot (Tokyo). 1984 Oct;37(10):1231-7 [6501094.001]
  • [Cites] J Antibiot (Tokyo). 1975 Oct;28(10):727-32 [1102509.001]
  • [Cites] Lancet. 1989 Jul 22;2(8656):227 [2568561.001]
  • [Cites] Science. 1991 Jan 18;251(4991):283-7 [1702904.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4441-5 [8183928.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1116-23 [7913512.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):178-85 [9293448.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):907-13 [9508172.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5033-8 [9560223.001]
  • [Cites] Leuk Lymphoma. 1998 Sep;31(1-2):143-9 [9720724.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):718-21 [9722298.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):886-94 [10029080.001]
  • [Cites] Stem Cells. 2004;22(6):1111-20 [15536200.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):525-37 [15728109.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2825-31 [15805283.001]
  • [Cites] Cancer Treat Rev. 1981 Mar;8(1):63-87 [7248995.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1614-20 [10995008.001]
  • [Cites] Cell. 2000 Oct 13;103(2):253-62 [11057898.001]
  • [Cites] Kidney Int. 2001 Jan;59(1):3-16 [11135052.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Dec;17(8):635-50 [11127395.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):249-58 [11566616.001]
  • [Cites] Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S22-8 [11583941.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6172-80 [11593425.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2121-8 [11597394.001]
  • [Cites] Blood. 2002 Jul 15;100(2):654-60 [12091361.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2887-92 [12912932.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15113-8 [14657335.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):37-51 [14766125.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Blood. 2004 May 15;103(10):3905-14 [14764536.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2336-47 [15136596.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1145-50 [15126317.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1420-4 [15365568.001]
  • [Cites] Leuk Res. 1986;10(8):1007-13 [3528680.001]
  • (PMID = 16195324.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / K08 CA104882; United States / NCI NIH HHS / CA / K08 CA104882-01A1; United States / NCI NIH HHS / CA / CA82156; United States / NCI NIH HHS / CA / CA104882-01A1; United States / NCI NIH HHS / CA / CA96696
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 624KN6GM2T / temsirolimus; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1895910
  •  go-up   go-down


91. Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group: Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol; 2007 Sep;29(9):627-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
  • We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product.
  • Allergic reactions were significantly associated with younger age, white race, and standard-risk acute lymphoblastic leukemia.
  • [MeSH-major] Asparaginase / therapeutic use. Bacterial Proteins / therapeutic use. Burkitt Lymphoma / drug therapy. Escherichia coli / enzymology. Hypersensitivity / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Erwinia / enzymology. Humans. Infant. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2007 Sep;29(9):587-8 [17805029.001]
  • (PMID = 17805038.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-05587; United States / NCI NIH HHS / CA / CA-07431; United States / NCI NIH HHS / CA / CA-11233; United States / NCI NIH HHS / CA / CA-15525; United States / NCI NIH HHS / CA / CA-15898; United States / NCI NIH HHS / CA / CA-15989; United States / NCI NIH HHS / CA / CA-20549; United States / NCI NIH HHS / CA / CA-25408; United States / NCI NIH HHS / CA / CA-28383; United States / NCI NIH HHS / CA / CA-28439; United States / NCI NIH HHS / CA / CA-28476; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-29293; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-30969; United States / NCI NIH HHS / CA / CA-31566; United States / NCI NIH HHS / CA / CA-32053; United States / NCI NIH HHS / CA / CA-33587; United States / NCI NIH HHS / CA / CA-33603; United States / NCI NIH HHS / CA / CA-33625; United States / NCI NIH HHS / CA / CA-53128; United States / NCI NIH HHS / CA / CA-69177; United States / NCI NIH HHS / CA / CA-69428
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


92. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ: Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood; 2007 Sep 15;110(6):1924-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
  • To determine whether the leukemia-associated Wilms tumor antigen (WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (SCT) for acute lymphoblastic leukemia (ALL), we studied CD8(+) T-cell responses to WT1 in 10 human lymphocyte antigen (HLA)-A*0201-positive ALL patients during the early phase of immune recovery after SCT (days 30-120).
  • [MeSH-major] Burkitt Lymphoma / therapy. Graft vs Leukemia Effect. Immunologic Memory. Stem Cell Transplantation. T-Lymphocytes / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. CD8-Positive T-Lymphocytes. Child. Cytomegalovirus / pathogenicity. Cytomegalovirus Infections / immunology. Cytomegalovirus Infections / therapy. Cytomegalovirus Infections / virology. Female. Graft vs Host Disease. HLA-A Antigens / metabolism. HLA-A2 Antigen. Humans. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Donors. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 May 15;174(10):6088-94 [15879103.001]
  • [Cites] Immunity. 1999 Aug;11(2):183-90 [10485653.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2807-14 [10679124.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] J Clin Immunol. 2000 May;20(3):195-202 [10941827.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1480-9 [10942395.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2458-64 [10946271.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3126-32 [11049993.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):549-56 [10952724.001]
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s [11300470.001]
  • [Cites] Methods Mol Med. 2002;68:223-37 [11901505.001]
  • [Cites] Cytotherapy. 2002;4(1):29-40 [11953039.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5455-64 [12023339.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):1014-21 [16338624.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):56-65 [16371020.001]
  • [Cites] Blood. 2006 Jan 1;107(1):205-12 [16144796.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Clin Immunol. 2006 Aug;120(2):121-8 [16766227.001]
  • [Cites] Cytotherapy. 2007;9(3):245-51 [17464756.001]
  • [Cites] Acta Haematol. 1999;102(2):72-6 [10529509.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):783-8 [12732885.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1988-95 [12743153.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):56-61 [12894852.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Jan;18(1):165-6 [14603333.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):91-105 [14750075.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57 [14752779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):839-46 [14767500.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):481-8 [15160909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2794-800 [15226184.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2195-204 [8630379.001]
  • [Cites] Blood. 2005 Jan 15;105(2):865-73 [15280205.001]
  • [Cites] Leukemia. 2005 Feb;19(2):268-74 [15538407.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3771-81 [8706023.001]
  • [Cites] Science. 1996 Oct 4;274(5284):94-6 [8810254.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):560-5 [8992968.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1751-67 [9292508.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2197-207 [9490709.001]
  • [Cites] Nat Med. 1999 Jul;5(7):839-42 [10395333.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6571-6 [15905493.001]
  • (PMID = 17505014.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501963
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC1976363
  •  go-up   go-down


93. Bendall LJ, Baraz R, Juarez J, Shen W, Bradstock KF: Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Res; 2005 Apr 15;65(8):3290-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia.
  • The chemokine stromal-derived factor-1alpha (SDF-1alpha) regulates leukemic cell motility and proliferation; however, the importance of these functions in the growth and dissemination of leukemia is unclear.
  • We examined SDF-1alpha-mediated responses of cells from 27 cases of acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Burkitt Lymphoma / enzymology. Burkitt Lymphoma / pathology. Chemokines, CXC / pharmacology. Chemotaxis, Leukocyte / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism
  • [MeSH-minor] Adolescent. Adult. Animals. B-Lymphocytes / drug effects. B-Lymphocytes / pathology. Calcium / metabolism. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Chemokine CXCL12. Child. Child, Preschool. Female. Humans. Infant. Integrin alpha4beta1 / metabolism. Integrin alpha5beta1 / metabolism. MAP Kinase Signaling System / drug effects. Male. Mice. Mice, Inbred NOD. Mice, SCID. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15833862.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Cxcl12 protein, mouse; 0 / Integrin alpha4beta1; 0 / Integrin alpha5beta1; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


94. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A, Jeddi-Tehrani M, Mellstedt H, Rabbani H, Shokri F: Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Jul;49(7):1360-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.
  • Over-expression of ROR1 gene, a member of the receptor tyrosine kinase family, has recently been reported in B-cell chronic lymphocytic leukemia.
  • In the present study, the expression profile of ROR1 and WT1 was investigated in different immunophenotypic subsets of B-cell acute lymphoblastic leukemia (B-ALL) patients.
  • [MeSH-major] Burkitt Lymphoma / pathology. Receptor Protein-Tyrosine Kinases / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Iran. RNA, Neoplasm / analysis. Receptor Tyrosine Kinase-like Orphan Receptors. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / WT1 Proteins; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  •  go-up   go-down


95. Tsapis M, Lieb M, Manzo F, Shankaranarayanan P, Herbrecht R, Lutz P, Gronemeyer H: HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol; 2007;39(7-8):1500-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
  • We have compared the growth inhibitory and apoptogenic potential of the pan-HDACi SAHA and the sub-class I selective HDAC inhibitor MS275, as well as valproic acid (VPA) on glucocorticoid sensitive and resistant B (B-ALL) and T (T-ALL) cell acute lymphoblastic leukemia cells and patients blasts.
  • In contrast, to our previous results with U937 acute myeloid leukemia (AML) cells which showed a similar activity of MS275 and SAHA in growth inhibition and apoptosis induction, both B and T-ALL cells were much more efficiently killed by SAHA and VPA than by MS275.
  • [MeSH-major] Apoptosis. Benzamides / pharmacology. Burkitt Lymphoma / pathology. Drug Resistance, Neoplasm. Glucocorticoids / pharmacology. Histone Deacetylase Inhibitors. Hydroxamic Acids / pharmacology. Leukemia-Lymphoma, Adult T-Cell / pathology. Pyridines / pharmacology

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499001.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glucocorticoids; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Pyridines; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 1ZNY4FKK9H / entinostat; 58IFB293JI / vorinostat; 614OI1Z5WI / Valproic Acid; 7S5I7G3JQL / Dexamethasone; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


96. D'Achille P, Seymour JF, Campbell LJ: Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet; 2006 Nov;171(1):52-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
  • We present a series of 12 cases of de novo acute lymphoblastic leukemia (ALL) with translocation t(14;18)(q32;q21).
  • A Burkitt translocation was identified in 4 of the 12 cases by conventional cytogenetics but fluorescence in situ hybridization using a MYC probe identified a further three cases of MYC rearrangement: one with a cryptic t(8;14) involving the der(14)t(14;18), one showing MYC translocated onto a marker chromosome, and one associated with a t(8;9)(q24;p13) translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD19 / analysis. Antigens, CD20 / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Neprilysin / analysis. Sialic Acid Binding Ig-like Lectin 2 / analysis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074591.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD20; 0 / Sialic Acid Binding Ig-like Lectin 2; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 32
  •  go-up   go-down


97. Tarrand JJ, Keating MJ, Tsimberidou AM, O'Brien S, LaSala RP, Han XY, Bueso-Ramos CE: Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer; 2010 Feb 15;116(4):880-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia.
  • BACKGROUND: Epstein-Barr virus (EBV) infection has been associated with Richter transformation in patients with chronic lymphocytic leukemia (CLL).
  • METHODS: A direct isothermal mRNA amplification method was developed for detection of EBV latent membrane protein 1 (LMP1) mRNA transcriptional activity in the peripheral blood of 135 chronic lymphocytic leukemia patients and 98 hematologically healthy control subjects.
  • In a later cohort of patients after hematopoietic stem cell transplantation, 4 of 7 patients with Hodgkin lymphoma or Burkitt lymphoma had EBV LMP1 detected.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / metabolism. Bone Marrow / pathology. Bone Marrow / virology. Cell Line, Tumor. Female. Humans. Male. Middle Aged. RNA, Messenger / metabolism. RNA, Viral / metabolism

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Epstein Barr Virus, Chronic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052729.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Messenger; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


98. Escher R, Wilson P, Carmichael C, Suppiah R, Liu M, Kavallaris M, Cannon P, Michaud J, Scott HS: A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia. Blood Cells Mol Dis; 2007 Jul-Aug;39(1):107-14
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pedigree with autosomal dominant thrombocytopenia, red cell macrocytosis, and an occurrence of t(12:21) positive pre-B acute lymphoblastic leukemia.
  • Interestingly, in the youngest generation, a 2-year-old boy presenting with these familial features has developed acute lymphoblastic leukemia characterized by a t(12;21) translocation.
  • [MeSH-major] Anemia, Macrocytic / genetics. Burkitt Lymphoma / genetics. Chromosome Disorders / genetics. Genetic Predisposition to Disease. Pedigree. Thrombocytopenia / genetics
  • [MeSH-minor] Adult. Child, Preschool. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 21 / genetics. Core Binding Factor Alpha 2 Subunit. Family. Female. Genes, Dominant. Hematopoiesis / genetics. Humans. Infant. Male. Middle Aged. Nuclear Proteins. Transcription Factors. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434765.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Nuclear Proteins; 0 / RUNX1 protein, human; 0 / Transcription Factors; 0 / ZFPM1 protein, human
  •  go-up   go-down


99. Takenokuchi M, Saigo K, Nakamachi Y, Kawano S, Hashimoto M, Fujioka T, Koizumi T, Tatsumi E, Kumagai S: Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18). Acta Haematol; 2006;116(1):30-40
Cellosaurus - a cell line knowledge resource. culture/stock collections - UTree-O2 (CVCL_W195) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
  • Peroxisome proliferator-activated receptor-gamma (PPARgamma), a member of the nuclear receptor superfamily, has been detected in several human leukemia cells.
  • We investigated the expression of PPARgamma and the effects of PPARgamma ligands on UTree-O2, Bay91 and 380, three B-cell acute lymphoblastic leukemia (B-ALL) cell lines with t(14;18), which show a poor prognosis, accompanying c-myc abnormality.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Burkitt Lymphoma / metabolism. Chromans / pharmacology. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. G1 Phase / drug effects. PPAR gamma / biosynthesis. Thiazolidinediones / pharmacology. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Female. Gene Expression Regulation, Leukemic / drug effects. Humans. Ligands. Male. Prognosis. Proto-Oncogene Proteins c-myc / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - 380 (CVCL_1047) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Bay91 (CVCL_M658) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16809887.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Ligands; 0 / MYC protein, human; 0 / PPAR gamma; 0 / Proto-Oncogene Proteins c-myc; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


100. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J, GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK): Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia; 2006 Dec;20(12):2155-61
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
  • Adult patients with acute lymphoblastic leukemia (ALL) and t(1;19)/E2A-PBX1 or t(4;11)/MLL-AF4 have a poor outcome.
  • [MeSH-major] Burkitt Lymphoma / genetics. Burkitt Lymphoma / therapy. Hematopoietic Stem Cell Transplantation. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Basic Helix-Loop-Helix Transcription Factors / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 19 / genetics. Chromosomes, Human, Pair 4 / genetics. DNA-Binding Proteins / genetics. Female. Histone-Lysine N-Methyltransferase. Humans. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Prospective Studies. Proto-Oncogene Proteins / genetics. Transplantation, Homologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039234.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / TCF3 protein, human; 0 / pbx1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down






Advertisement